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1.1. STEM CELLS 
Stem cells are a very important resource in terms of cell renewal. They are 
considered as the organizational units responsible for the development and 
regeneration of tissues and organs, and are broadly defined as clonogenic cells, 
because they can both proliferate independently as well as to differentiate into 
various cell populations. In fact, in vivo they maintain themselves thanks to an 
asymmetric cell division: after the cell duplication, a daughter cell becomes 
“committed” and moving towards a specific cell type, while the other one 
remains undifferentiated, to maintain a constant reserve of potentially usable 
cells (He et al., 2009; Sylvester and Longaker, 2004). Stem cells are generally 
classified into four different types, according to their degree of "potency", 
understood as the ability to differentiate and specialize in different cellular 
types: totipotent, pluripotent, multipotent and unipotent cells (Fig.1). 
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Fig 1 - Different grade of “potency” of stem cells. Starting from the morula and blastocyst stage, in which 
stem cells are respectively totipotent and pluripotent, so potentially able to generate in the first case all 
individual tissues including extra embryonic (placenta) tissue and the second case any kind of cellular 
types, the cells progressively specialize and become committed, able to generate only a few cell types. 
 
Totipotent cells have the potential to give rise to a whole organism, including 
extra-embryonic (placenta) tissue, so they are totally “un-committed”, and 
represent the earliest stage of un-differentiated cells. Pluripotent cells are able 
to differentiate into all cells that constitute an individual but they don’t give rise 
to extra-embryonic tissue; being able only to generate all three germ layers 
cells. Multipotent stem cells have a much less potency because they have the 
ability to differentiate only in certain cell types (i.e. the hematopoietic stem 
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cells), as these cells are already genetically directed towards a cell type. Finally, 
the unipotent cells are able to differentiate only in a specific differentiated class 
of cells. The latter represent the lowest potency level within the scenery of 
stem cells. 
Stem cells can also be divided in embryonic, fetal and adult stem cells, with 
respect to their potency and their developmental stage derivation (Czyz et al., 
2003). Embryonic stem cells are found in the embryo in a very early stage of 
development, and they are considered pluripotent stem cells. Fetal stem cells 
are derived from an embryo at the fetal stage, from the biological point of view 
there is not yet a definitive characterization, but available studies showed that 
they have intermediate characteristics between embryonic and adult. The adult 
stem cells are instead partially specialized cells, responsible for the regeneration 
of damaged tissues, as well as involved in the normal homeostasis of the tissue. 
The adult stem cells constitute a great therapeutic hope in man, since they 
could be drawn out from an individual, corrected and used in the patient for cell 
therapy, without incurring in ethical problems (Ellison et al., 2013). In recent 
years research using stem cells is moving on induced pluripotent stem cells 
(IPSc), adult cells already differentiated brought at the pluripotent stage, by 
inducing a "forced" expression of specific genes. One of the most applications 
of stem cells is in the care and treatment of a wide variety of movement 
disorders including Parkinson's disease (PD) or and Huntington's disease 
(Schwarz and Schwarz, 2010).  
Another important line of research that is increasingly being developed in 
recent years, is about a class of stem cells defined as mesenchymal stem cells 
(MSC), that are found in different points of the body and are able to generate 
bone tissue, cartilage or adipose tissues (Dimarino et al., 2013; Stewart and 
Stewart, 2013). Cultures of MSCs have already been established in the early 
1960s when fibroblastoid cells were discussed as supportive stromal cells within 
the hematopoietic bone marrow niche. Such cells, with a morphology similar to 
fibroblasts, with a low amount of cytoplasm, mitochondria, and a little 
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developed Golgi apparatus, are usually believed to be multi- or oligo-potent 
stem cells that can be expanded ex vivo and have the potential for 
differentiation into at least three cell types: osteocytes, chondrocytes, 
adipocytes (Minguell et al., 2000; Minguell et al., 2001). 
Despite the ethical problems concerning the use of human embryonic stem 
cells, their ability to generate any type of tissue present in the body make them 
a fundamental tool for basic research. Many research groups have been and are 
moving to the field of basic research using mouse stem cell to understand the 
mechanisms that underlie many biological and pathological processes that 
affect humans, being these cells an excellent reference model.  
 
1.1.1. MOUSE EMBRYONIC STEM CELLS 
“Pluripotential embryonic cells appear to give rise to both rapidly differentiating 
cells and others which like themselves, remain undifferentiated” (Stevens and 
Little, 1954).  
These words were used by Stevens and Little in 1954 while describing ovarian 
teratomas; several years later this description became the best definition of 
embryonic stem cell. The earliest pluripotent stem cells were isolated from 
teratocarcinoma, complex malignant tumors composed by different types of 
cells resulting from three germ layers and undifferentiated cells, and were 
called embryonic carcinoma (EC) cells (Martin and Evans, 1975). The limit of 
using these cells as a model is their instability in culture, because of their 
tendency in vitro to aneuploidy (Martin, 1981). This causes the limited use of 
these cells for genetic engineering because they rarely colonize the germ line. 
In 1981, two reports for the first time showed that was possible to isolate from 
the inner cell mass (ICM) of a mouse embryo at the blastocyst stage cells that 
were able to grow in vitro, and to establish permanent mouse stem cell lines. 
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These embryonic stem cells (ESC) were derived by culturing blastocyst on a 
feeder layer (mitotically inactivated fibroblasts were used) in a specific cell 
medium (Evans, 1981; Martin, 1981).  
It is important to distinguish ESC of the inner cell mass from the epiblast-stem 
cells (EpiSC) , since it has been demonstrated that, although both are 
embryonic stem cells, only the first have the ability to colonize the germ line 
when injected in recipient blastocysts. Epiblast-stem cells are derived from the 
epiblast at the post-implantation stage and can contribute to chimeras but not 
to the germ line; they are less pluripotent compared to inner cell mass stage 
(Zhou et al., 2010). It has been demonstrated that appropriate synergy of 
epigenetic and signaling modulations could convert EpiSC to the earlier mESC 
pluripotency state, providing new insights into mechanism of pluripotency 
regulation (Zhou et al., 2010). 
Mouse embryonic stem cells (mESC) are pluripotent stem cells with the 
capability of self-renewal and differentiation; in vitro they can be propagated as 
a homogeneous, uncommitted cell population for several passages without 
losing their pluripotency and their chromosomal stability (Prelle et al., 2002). 
Mouse ESC are cultured in vitro on a feeder layer of mouse embryonic fibroblast 
(MEF); MEFs must be inactivated prior to use by using -irradiation or 
mitomycin-C treatment; both methods produce feeder layers suitable for the 
maintenance of undifferentiated cells. Mouse ESCs in vitro show distinct 
morphological features: they grow in compact multilayered colonies, have a 
high nuclear:cytoplasm ratio and show alkaline phosphatase activity, a 
phenotypic marker of pluripotent stem cells, shared by induced pluripotent stem 
cells (iPSCs), and embryonic germ cells (EGCs). mESCs express high conserved 
membrane markers, such as SSEA-1 (stage-specific embryonic antigen-1) 
(Solter and Knowles, 1978), a surface protein that can selectively bind or 
adhere to other signal molecules. SSEA-1 was identified by using a monoclonal 
antibody, recognizing a defined carbohydrate epitope, and is involved in 
controlling cell surface interactions during development in vivo. This marker 
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decreases during differentiation in mouse, while increases in human ESC (Zhao 
et al., 2012). mESCs also show as markers of pluripotency some transcription 
factors, that are crucial for gene regulation; some of these are usually present 
in an inactive form, but are activated when are generating specific activation 
signals. The most important transcription factors involved in maintaining 
pluripotency in mouse are OCT4, Sox2 and Nanog. OCT4 (octamer-binding 
protein 4) is a member of the Oct family of POU transcription factors; it has 
been demonstrated that the POU domain is critical for the function of DNA 
transcription’s regulation, while the region outside the POU domain is not of 
fundamental importance for DNA binding and has little sequence conservation. 
A different expression of OCT4 is been observed during embryogenesis, when 
the inner cell mass differentiates into epiblast and hypoblast in the first days of 
development; its expression is limited to pluripotent stem cells and germ line 
cells (Zhao et al., 2012). SOX-2 is a member of the SOX gene family that 
belongs to the HMG (high mobility group) box transcription factors group, and 
interacts with POU domain proteins. Unlike OCT4, SOX-2 is expressed in 
pluripotent stem cells as well as some unipotent and multipotent stem cells (Liu 
et al., 2013). 
Nanog is a transcription factor that works in maintaining pluripotency as well as 
self-renewal in mouse, and also in human ESC, and has also been described to 
be required for the maintainance of pluripotency in mouse EpiSC (Mitsui et al., 
2003). Nanog expression is known to fluctuate in ESC, and different levels of 
Nanog seem to correlate with ESC capability to respond to differentiation 
promoting signals. Its expression is early down-regulated during differentiation, 
and is able to maintain self-renewal independently of the LIF/Stat3 pathway 
(Do et al., 2013; Medvedev et al., 2012; Zhao et al., 2012). If Nanog and Oct4 
are essential to maintain pluripotency, LIF activation pathway plays an 
accessory role. mESCs in vitro are grown by using a specific cytokine, leukemia 
inhibitory factor (LIF), that is able to maintain the stemness of the cells. It is a 
soluble glycoprotein of the interleukin-6 (IL-6) family of cytokines, which acts 
via membrane-bound receptor signaling complex protein, to regulate cell 
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functions by using cell signal transduction. The LIF receptor (LIFR) is formed by 
two subunits: gp130, which is common to all the cytokines from the IL-6 family, 
and LIFR (or gp190), specific for LIF. Despite the JAK-Stat3 pathway is 
essential and sufficient to maintain pluripotency of cells mediating LIF signal, 
how the signal is transmitted to the transcription factors that mediate the 
pluripotency it is not yet clear. In mESC it has been demonstrated that the 
presence of LIF is able to activate an intracellular pathway by using different 
transduction ways (Niwa et al., 2009; Pan and Thomson, 2007)(Fig 2). 
 
 
Fig. 2- Pathways of LIF signal in pluripotent stem cells. LIF signal is integrated into the core regulatory 
pathway using two parallel ways: the JAK-Stat3 way, that activates Klf4 and then Sox2, and the PI3K 
pathway that activates Tbx3 and then usually Nanog (Niwa et al., 2009). MAPK-kinase, on the other hand, 
prevents the up-regulation of Klf4 expression by controlling Tbx3 and Nanog. 
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LIF signal actives three pathways: JAK-Stat3, PI3K-Akt and MAPK pathway. 
Among them, the first one is activated exclusively by LIF signal; instead the 
other ones are also regulated by different intermediates. It has been show that 
LIF signal is integrated into the core regulatory pathway using two parallel 
ways: the JAK-Stat3 way, that activates Klf4 and then Sox2, and the PI3K 
pathway that activates Tbx3 and then usually Nanog (Niwa et al., 2009). MAPK-
kinase, on the other hand, prevents the up-regulation of Klf4 expression by 
controlling Tbx3 and Nanog. In the absence of LIF, the activation of Stat3 or 
the overexpression of Nanog is sufficient to maintain the pluripotency and self-
renewal. Stat 3 is activated by Janus Kinase 1 (JAK1), protein, and has been 
shown that STAT3 directly binds to the Oct4 and Nanog distal enhancers, to 
modulate their expression in maintaining pluripotency in mouse embryonic stem 
cell (Do et al., 2013). There is a relation between different transcription factors 
involving in maintaining pluripotency: in the cascade of events Tbx3 (deriving 
from PI3K cascade) and Klf4 (deriving from JAK cascade) are upstream whereas 
Nanog is downstream to Tbx3, to activate Oct4 expression. This complex 
regulation composed by parallel pathways and overlapping functions to control 
the self-renewal is necessary to maintain the pluripotency of cells under specific 
stimuli. It has been highlighted that the absence of IL-6 family members, or the 
inactivation of STAT3, can be sufficient to promote ESC to spontaneously 
differentiate in vitro (Wobus and Boheler, 2005). 
Pluripotent stem cells usually are subjected to a series of assay in vitro e in vivo 
to clarify their stemness, as can be summarized in the Tab 1. 
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Tab 1- Most common assays used to show the stemness of stem cells.  
 
In addition to the morphology of the colonies in vitro and markers of 
pluripotency, that are generally investigated through immunoistochemistry 
assays and molecular biology techniques, such as staining for standard 
pluripotency markers and real-time PCR, another common test used to show 
the pluripotency of mESC is the ability to produce a teratoma in vivo. Teratoma 
demonstrates the ability of cells to differentiate into the three germ layers 
(Przyborski, 2005). Teratomas are benign tumors characterized by rapid growth 
in vivo, and consist of multiple tissues organized often in quite complex 
structures. There are several protocols to describe the procedures that must be 
observed for the injection of stem cells in the mouse in order to obtain 
teratomas, and mice with a compromised immune system are used 
(NOD/SCID/ -common chain NSG, or nude mice) to avoid rejection. mESCs can 
be injected subcutaneously or intraperitoneally, only in some cases the 
preferred site of injection is the kidney capsule or testes. Four to six weeks 
post-injection teratomas will become palpable (Zhang et al., 2012) and 
removed (Fig 3). 
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Fig 3 - Teratoma formation in immune-compromised mouse. mESCs can be injected subcutaneously and 
four to six weeks post-injection teratomas will become palpable . 
 
Analyzing the teratoma from a histological point of view, can be observed that 
cells derived from all three sheets of embryological derivation will be present. 
The same in vitro demonstration of pluripotency of stem cells can be obtained 
by embryo-body (EB) formation (Marti et al., 2013). When mESCs are grown in 
absence of LIF in vitro, or without a feeder-layer that permits the maintenance 
of stemness, ESCs tend to differentiate spontaneously and to aggregate in a 
three-dimensional formation called embryo-body, a structure that facilitates 
multicellular interactions. EB consists of endodermal, ectodermal and 
mesodermal tissues and can be considered as a model of in vitro differentiation 
(Kurosawa, 2007). Different methods to generate EBs have been described, and 
the most common protocols are the suspension culture in bacterial-grade petri 
dishes, culture in methylcellulose semisolid media, and culture in handing-
drops. The EBs obtained can then be analyzed to assess the presence of cells 
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pertaining to the three germ layers, thus demonstrating their ability to 
differentiate in vitro. 
Finally, another assay to test the stemness of ESC in vivo is the injection in 
blastocysts to produce a chimera. Chimera refers to a single organism 
composed by two or more different population of genetically distinct cells. The 
contribution to the chimera organism by each parental cell type can vary in the 
various tissues and organs. The first experimental mouse chimera was done in 
the 1960s, by aggregating two or more whole 8-cells embryos, to obtain a 
single individual consisting of a mixture of parental embryos (Mintz, 1962; 
Tarkowski, 1961). After that, chimera organisms were produced also with 
tetraploid host embryos; tetraploid embryos were not able to produce viable 
offspring, but they have the ability to contribute to functional extra-embryonic 
tissues. When ESCs are introduced into mouse tetraploid embryos, they 
colonize the proper embryo and are able to give rise to the offspring, supported 
by extra-embryonic tissues deriving by tetraploid cells (Wang et al., 1997). 
With regard to the cell cycle, ESCs show unusual features, composed by an S 
phase, a short G1 phase and the absence of the G1/S checkpoint. Cell division 
and proliferation are controlled by mechanism ensuring the accurate 
transmission of the genetic information from generation to generation. So far, 
despite the great progress in the knowledge of the cell cycle of ES cells, many 
regulatory mechanisms remain unknown (Abdelalim, 2013). Cell cycle in murine 
stem cell is rapid, estimated at 8-10 hours and is assumed to be similar to that 
of peri-implantation embryos; mESCs have a truncated gap phases, and an 
unusually high proportion of asynchronously dividing cells are in S-phase (more 
or less 65%) when compared with G1 (more or less 15%). It has been 
hypothesized that proteins directly regulating DNA replication might also 
stabilize pluripotency, and it’s possible that the high order chromatin 
rearrangements that also occur during S-phase in order to allow DNA replication 
to proceed, could provide epigenetic modifications that stabilize the pluripotent 
state (Hindley and Philpott, 2013).  
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1.2. GENE THERAPY 
The term “gene therapy” potentially includes different approaches to cure 
inherited diseases. The US Food and Drug Administration (FDA) defines gene 
therapy as “products that mediate their effects by transcription and-or 
translation of transferred genetic material and/or by integrating into the host 
genome and that are administered as nucleic acid, viruses or genetically 
engineering organism” (Wirth et al., 2013). 
The possibility to use viral agents as "carriers" of genetic material into cells in 
order to develop gene therapy protocols has its roots in the early 60s. Since 
then, there have been many advances on the topic, and the early 90s saw the 
development of tools for recombinant DNA technologies, to develop innovative 
approaches of gene therapy using recombinant DNA (Cotrim and Baum, 2008; 
Mali, 2013). 
Gene therapy can potentially be applied during embryonic (germ-line therapy) 
or fetal life or only into specific somatic cell (somatic gene therapy); using the 
second approach, DNA correction would not be passed into subsequent 
generation (Orkin, 1986). The difference is substantial, in that current 
legislation, for human individual, allows only somatic gene therapy.  
The two main methods can be used for gene therapy are the ex vivo and in 
vivo approach. In the ex vivo approach cloned genes are transferred in vitro 
into cells explanted from the body, and in this way the rejection by the immune 
system can be prevented since the cells are autologous. Gene therapy in vivo is 
carried out in all those cases in which cells cannot be manipulated in vitro or 
removed and re-implanted, such as those of the brain or heart, and also more 
difficult to apply. In this case, the correction procedure is performed in the 
body, via a suitable vector, administered either locally or systemically. 
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Somatic gene therapy represents the main topic of several lines of research, 
and the goal is to obtain a therapeutic effect by introducing the genetic material 
in the cells to be corrected, without causing toxicity to these cells. With this 
aim, it is necessary to know the genetic damage to be replaced, the position of 
the rearrangement that involves the DNA sequence and the molecular 
characterization of DNA damage.  
 
 
 
1.3. GENE THERAPY APPROACHES TO THE 
CORRECTION OF HEREDITARY 
RECESSIVE DISESASES 
Gene therapy can be generally applied using three different approaches: gene 
addition, gene correction and gene knockdown.  
The gene addition therapy is applicable to diseases caused by gene recessive 
mutations in a single gene: it involves providing cells with an exogenous copy 
of the wild-type allele, whose expression gives the normal and functional 
protein, and this mechanism should rescue the cells from the disease 
phenotype. The rationale of this approach is straightforward, and could be 
applied to most recessive diseases and to those due to haploinsufficiency. 
There are two ways to implement this approach: either by insert a copy of the 
gene transcript (essentially a cDNA) randomly in the genome or by targeting 
the abnormal locus reconstituting the correct sequence (homologous 
recombination).  
A different strategy is needed for the diseases caused by dominant genetic 
mutations; in this way to give an extra-copy of the correct allele cannot be 
enough, so other gene therapy approaches, able to destroy or inactivate the 
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abnormal protein or its production, have been investigated by using a knockout 
approach. 
  
1.3.1. FIRST GENERAL APPROACH: random 
inserting a gene by viral vectors 
In theory, every procedure allowing the random insertion of a DNA fragment 
into the affected cells could work. However, today mainly methods based on 
modified virus vectors are used and will be briefly reviewed here. 
First of all, the viral life is divided in two times, the infection time and the 
replication time. The first one is the introduction of the viral genome into the 
cells; the second one is given by the production of regulatory protein and the 
expression of viral genes. Using viruses for gene therapy is necessary to 
engineer a viral vector to carrier a therapeutic sequence in place of viral 
genome. The virus is rendered unable to reproduce themselves, to prevent the 
spread of recombinant viruses (defective virus); its genome is engineered with 
recombinant DNA techniques, and the individual plasmids are co-transfected 
into particular cell lines capable of producing recombinant viral particles 
(packaging lines). These lines are able to complement the defects introduced 
into the viral genome. This step is crucial to be able to control any hope of 
recovering from the virus in active viral particles (Kay, 2011).  
The concentration of carriers is measured by the expression of the title. The 
main advantage consists in the high transduction efficiency (up to 100% of the 
cells). Once produced the recombinant viral DNA, this may be analyzed first, 
and then used. In gene therapy is important measure the amount of viral 
particles used in order to obtain the best efficiency of infection even with a low 
toxicity to the cells that are infected. Unfortunately, most of viruses used are 
integrated in the genome of the target cell in a random manner; this leads to 
incontrollable mutational events in the target genome. This evidences led over 
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the years to develop recombinant viral DNA with the lowest possible toxicity for 
the cells (Boeckle and Wagner, 2006; Huang and Kamihira, 2012). 
The most used viruses for gene therapy in the last ten years can be grouped in 
three most important classes: retroviruses, which include lentiviruses and 
oncoviruses, adenoviruses and adeno-associated viruses.  
Classical retroviruses are able to infect only dividing cells; they are lipid-
enveloped particles composed by homodimer of linear single-strand RNA 
sequences (no more than 11 kb). They integrate themselves randomly in the 
target genome. (Gabriel et al., 2011b). Because of their RNA-sequence, once 
into the infected cells they have to be retro-transcribed into linear double-
strand DNA to integrate permanently in the genome. The virus then exploits the 
normal processes of transcription and translation in order to express the viral 
genes.  Different types of viruses are included in the retrovirus family: 
oncoviruses, lentiviruses and spumaviruses. In the recombinant DNA molecule 
inserted into the structure of the virus, some viral genes are replaced with the 
cDNA of the target gene; in this way the vector is not able to produce the 
proteins necessary for another cycle of infection. So the carrier is rendered 
defective for replication; viral proteins necessary for initial viral infection are 
given in trans by packaging cells or helper virus. Generally, up to eight kb of 
exogenous DNA can be inserted and expressed by the viral vector. One of the 
first promising results came in 2000 when the ability to cure SCID patients 
using retro-virally transduced autologous bone marrow was demonstrated; 
despite the initial enthusiasm, some of these patients developed leukemia after 
treatment, because of high activation capacity exerted by the LTR regions 
towards genes flanking the insertion site (Kay, 2011). Among retroviruses, 
lentiviruses are now the most used in gene therapy; their genome structure is 
more complex because is composed also by some regulatory genes, necessary 
for genome expression. Unlike the classical retroviruses, lentiviral vectors are 
able to target also non-dividing cells and have a LTR that lack a strong 
enhancer (Sakuma et al., 2012). The first vector was obtained by engineering 
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the HIV-1 virus to transduce lymphocytes (Pluta and Kacprzak, 2009). It has 
been show that lentiviral vectors efficiently transduce differentiated epithelial 
tissues of human, rodents and other species, but at the same time the safety of 
this approach has yet to be definitively established (Kay, 2011). Besides, both 
the need for retro-transcription step of the genome sequence to DNA and the 
limited size of the construct that can be inserted in place of the viral genome, 
make these carriers still subject to debate (Kay, 2011). 
Adenoviruses are characterized by non-enveloped icosahedral structure, and 
are composed by linear double-stranded DNA genome of 30-40 kb. They are 
essentially composed by two different parts, the core and the capsid. The 
genome is about 36 kb, composed by coding regions for genes expressed early 
and late, flanked by inverted terminal repeat (ITR) that are used as replication 
origins. Adenovirus is able to infect both dividing cells and not dividing cells, 
and after the cell infection the virus does not integrate into the host genome 
but remains episomal. This feature gives greater security to be used in gene 
therapy (Noureddini and Curiel, 2005; Noureddini et al., 2006). Recombinant 
adenovirus is constructed by using DNA molecule of interest inserted in the viral 
genome loci; the first adenoviral vectors used had a deletion that rendered the 
virus defective for replication. Over the years, the high applicability shown by 
these carriers has led to engineer their genomic sequence in order to maintain 
the high infective capacity while getting more manageable vectors from a safety 
point of view, passing from the vectors so-called first-generation to those of the 
third-generation. Among the latter, a class of recombinant adenoviruses such as 
Helper Dependent or Gutless is currently used as therapy vector. In them, all 
viral genes have been deleted leaving only the ITR regions and the packaging 
sequence to the left of the gene of interest, while the replicative functions are 
provided in trans by a “donor”, such as an helper virus. In this way it’s possible 
to keep the structure by replacing the viral genes needed for replication with 
the genes of interest that have to be between 100 bp and 36 kb in length. The 
disadvantages are that they have transient expression and, and in vivo show 
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high immune response. In fact, they can induce toxicity at the concentration 
required to obtain a therapeutic effect (Kay, 2011). 
Adeno-associated viruses (AAV) are DNA single-stranded viruses, non-
pathologic, that need a helper virus for replication and for the completion of 
their life cycle. Their genome structure is very simple: they are composed by 
two genes, cap and rep, respectively deputies to viral replication and packaging 
of the genome, and two inverted terminal repeat regions (ITR). Adeno-
associated viral vectors are able to infect both dividing and non-dividing cells, 
and are able to remain episomal. This feature makes them a good tool for 
applications in the field of gene therapy (Dismuke et al., 2013). Also in this way 
the viral genome in the hybrid vectors is replaced by genomic sequences of 
interest which can then be transported within the cell, the only limit being the 
size. In fact, the insert size is around 4 kb (Coura Rdos and Nardi, 2007). The 
main advantages are the fact that AAV in vivo are not pathogenic to humans, 
are easily obtained with high titers and allow a high efficiency of gene transfer; 
on the other hand, can convey only small molecules and can cause a high 
immune response. To overcome this last limitation, various strategies are being 
tested (Hareendran et al., 2013). 
Another family of viral vectors widely used for clinical trials related to the 
central nervous system is the Herpes Simplex Virus (HSV-1). These have the 
capacity to establish latent infections in certain districts of the organism, and 
this capacity is exploited in a controlled manner in order to activate the 
expression of genes inserted into their genome. 
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1.3.2. THE SECOND APPROACH: targeting the 
abnormal locus by homologous 
recombination (HR) means 
Historically, homologous recombination (HR) in mammals has been developed 
in mouse ESC. The beauty of this technique is that it is possible to perfectly 
correct the DNA abnormality, restoring the original wild type DNA sequence 
(Babinet and Cohen-Tannoudji, 2001; Capecchi, 1989; Mansour, 1990). In this 
way, the gene will be under the control of its own normal regulatory sequences, 
eliminating the bias of a random insertion and avoiding the silencing mediated 
by the cell recognition of viral sequences. In addition, any interference by 
exogenous viral sequences, which have been linked to cancer, will be 
prevented.  
The HR approach is known also as gene targeting, and has been used for 
several years to manipulate mouse genome to create knock-in and knock-out 
mice (Wong and Chiu, 2011). This strategy for gene therapy is better than 
supplying an extra copy of the gene, because the correction at the endogenous 
genomic locus leads to a functional gene in its natural environment with a 
natural regulation of expression. Furthermore, when cells are corrected in the 
right target sequence, the corrected gene will be expressed indefinitely 
(Templeton, 1996). HR is based on pairing of DNA sequences, exploiting the 
homology of the complementary regions; this interaction therefore allows the 
substitution of the nucleotides of the genomic region damaged with a correct 
DNA sequence (Fig 4).  
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Fig 4 – Schematic homologous recombination mechanism. A double strand break is identified and 
replaced by using homologous DNA donor as template; in this way a damage can be corrected (red 
sequence). 
 
Different vectors types are used for HR, and are all constructed to allow binding 
of the homologous regions to the target site of interest, and to replace the 
mutated endogenous region with an exogenous normal fragment. Vectors 
usually present also a marker of resistance, to select cells in vitro where the 
insertion of the correct sequence has occurred. It has been shown that in ESCs 
the frequency of HR is much higher than in somatic cells, and for this reason 
mESC became the preferential material for this kind of genetic manipulation. HR 
in mESCs led to the generation of thousands of knockout and knock-in mice, 
but, so far, has not been used in clinical trials, due to the extremely low 
efficiency of the HR in somatic cells. 
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1.3.2.1. New technologies for homologous recombination 
Since the homologous recombination occurs even in vitro with very low 
efficiency, in the last few years mechanisms of gene targeting to increase the 
recombination efficiency were developed. The rationale of these advances was 
the idea that, by causing a breakage in the DNA double helix, within the region 
of interest increases HR events.  
The most common approaches to gene targeting are Zinc-Finger Nuclease 
(ZFN), Transcription Activator-Like Effector nuclease (TALEn) and Clustered 
Regularly Interspaced Short Palindromic repeats (CRISPR); all of them are able 
to identify a specific DNA region in the genome and thanks to a linked nuclease 
these complexes are able to cut in the preselected region. It has been shown 
that this approach increases the efficiency of homologous recombination up to 
10 -1 10-6 (Mali and Cheng, 2012). 
 
1.3.2.1.1. Zinc Finger Nuclease (ZFN) 
The zinc-finger structure was described for the first time more than 20 years 
ago as repeated zinc-binding motifs, containing cysteine and histidine ligands; 
in the structure of the protein one or more zinc residues are necessary for the 
stabilization of conformation. Since that, different zinc-binding proteins that 
result from variations of the classic motif Cys2-Hys2 have been identified. They 
have the most variable functionality, from DNA or RNA binding to protein-
protein interaction, and are all characterized by high binding specificity to a 
target region. This structure has been engineered to obtain zinc finger 
nucleases, hybrid proteins composed by a DNA-binding domain and a non-
specific cleavage domain (usually is used Fok1): the first one is able to bind 
specific DNA sequences exploiting the specificity of interaction DNA-protein, 
while the second one is able to produce double-strand breaks in that genomic 
region (Carroll, 2011; Chou et al., 2012). Each motif, consisting of 
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approximately 30 amino acid, is able to recognize 3 nucleotides and is 
composed by an -helix and two -antiparallel sheets; the contact is made by 
the side chain of the -helix (Fig 5). 
 
 
Fig 5- Structure of the ZFN motif. The protein presents two anti-parallel -sheet and one -helix; the side 
chain of the -helix is responsible of the DNA-protein binding. 
 
The associated FokI nuclease works as a dimer: two adjacent and independent 
binding events (reverse and forward) must occur both in the correct orientation 
and with appropriate spacing, allowing dimer formation (Fig 6). To do that, two 
independent ZFNs have to bind DNA in the correct orientation and position. The 
dimerization of the nuclease triggers its activation and thus the production of a 
double-strand break in the genomic region comprised between the two target 
sites of ZFNs (Fig 6). 
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Fig 6 - Mechanism of action of ZFN motif. Each ZNF, shown as a colored circle, recognizes 3-4 
nucleotides. In this way, a ZNF motif is able to link a specific DNA sequence. FokI nuclease is activated by 
dimerization, so the customized ZNFs work in pair. The FOKI dimerization and its activation permits the 
production of a double-strand break in the region of interaction. 
 
Early studies on ZFN used three motif-array to bind a 9-bp target, given a cut 
specificity given by target region of 18bp. It has shown that a target site of 9-
18 bp is sufficient to target unique sequence in complex genome. More 
recently, studies using ZFN have been conducted using up to six ZFN-motifs, to 
increase the specific of break (Urnov et al., 2010). Furthermore, using this 
approach bi-allelic modification at the same time can be created. For many 
years ZFNs have been the main approach for gene targeting; despite the high 
affinity that characterizes the method, it has been shown that is sufficient for 
the DNA binding and cleavage only 60% homology of putative target region. 
This limits the use of the technique, because of the side-effects of off-target 
breaks. Two recent studies have showed that ZFNs cleaved off-target sites in 
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genome besides the in vitro predicted DNA sequence, and this might cause 
chromosomal instability and genotoxicity (Gabriel et al., 2011a; Pattanayak et 
al., 2011). In addition, repair of ZFN cleavage sites might lead to frequent 
mutations (Cathomen and Joung, 2008; Lombardo et al., 2007) and abnormal 
integrations of donor DNA (Hockemeyer et al., 2009). Nevertheless, using this 
approach the ability to correct DNA mutations associated with SCID (severe 
immunodeficiency), hemophilia B, sickle cell disease and anti-trypsin deficiency 
has been demonstrated. Furthermore, studies about inactivation of genes 
involved in the onset of Parkinson desease and HIV / AIDS have been reported 
(Gaj et al., 2013b). 
 
1.3.2.1.2. Transcription Activator-Like Effector Nuclease (TALEn) 
The transcription activator-like effector (TALE) family in plants forms a subset 
of proteins involved in the modulation of host gene expression; in fact 
pathogenic bacteria have developed this strategy to colonized host plants. 
The central region of these proteins shows the most fascinating and versatile 
feature of TALE. It is composed by a series of nearly identical 34/35 amino 
acids modules repeated in tandem (Fig 7); the hyper-variability is given by 
residues in positions 12 and 13; it is also referred to as the Repeat Variable Di-
residues (RVDs), and every motif of the repeat domain recognizes only one 
nucleotide and this provides a greater binding specificity than zinc-finger 
protein. 
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Fig 7 - Structure of the TALE protein. The repeat domain involves the central region of the protein and is 
composed by amino acids motifs repeated in tandem. 
 
 
TALEn are artificial complexes composed by the fusion of a transcription 
activator-like effector (TALE) DNA binding domain and an endonuclease, FokI 
(N) at the C-terminal end. In this way it is possible to take advantage of the 
high specificity of DNA-protein binding to create double-strand breaks by using 
the nuclease activity, in a way similar to ZFN technology (Fig 8). The 
mechanism of genome editing is the same: two anti-parallel TALEN (forward 
and reverse) bind DNA and permit the dimerization of FokI nuclease; the only 
target limitation seems to be the requirement that the binding site have to start 
with T (Gaj et al., 2013a). It has been highlighted that a spacer of 12–15 bp 
between the two target half-sites is optimal for high TALEN cleavage activity 
(Mussolino et al., 2011). 
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Fig 8 - TALEn genome editing mechanism. Left TALEn and right TALEn, each one linked to a FOKI 
nuclease, bind specific sequence DNA and cause dimerization of FOKI nuclease; its activation causes a 
double strand break in the region of interaction. 
 
Repair of double-strand DNA breaks induced by TALEn can be exploited to 
induce targeted insertion/deletion mutations (by non-homologous end-joining-
mediated repair) or specific substitutions or insertions (by homology-directed 
repair). Several groups have reported advances in genome editig using TALE-
based engineering in different organisms, such as zebra fish, rats, yeast, mouse 
and man. For instance, TALEns have been used to achieved gene targeting at 
sites that are usually refractory to HR in mouse ES, such as Y-chromosome 
genes (Wang et al., 2013). Recent works in vivo has shown that injection of 
TALEn mRNA into fertilized mouse oocytes can give a high percentage of pups 
with targeted deletion with efficiency between 10-77%. In vitro, using this 
technology, it has also been possible to construct cell-based disease models, 
using somatic cells or induced stem cells (IPS). Also for this technology, there is 
a possible toxicity given by the off-target break in the genome; a recent paper 
(Mussolino et al., 2011) has shown that for CCR5 human locus, TALEN revealed 
only minimal off-target activity as compared to the corresponding ZFN, 
suggesting that the TALEn platform enables the design of nucleases with single-
nucleotide specificity.  
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1.3.2.1.3. Clustered Regularly Interspaced Short Palindromic Repeats 
(CRISPR)  
More recently a new molecular RNA-interference mechanism has been 
discovered in bacteria, and it has been exploited to be used as a gene targeting 
mechanism in mammals, also in this way mimicking what occurs in nature. In 
fact, many bacteria and Achaea protect themselves from viruses or other 
genome invasion by using a genetic interference pathway. To do that, they use 
short RNA molecules to direct degradation of foreign nucleic acids; this 
protection mechanism is called “Clustered Regularly Interspaced Short 
Palindromic repeats” (CRISPR) associated protein (Cas) system (Richter et al., 
2012; Szczepankowska, 2012). Is not hard to see how this complex mechanism 
can be exploited for gene targeting. In fact, when Cas9, a protein of the type II 
CRISPR-Cas system, is complexed with two RNAs, trans-activating RNA 
(tracrRNA) and CRISPR RNA (crRNA), the sequence –specific endonuclease is 
activated causing a break in the target region genome. CRISPR locus is 
composed by short repeats, separated by non-repetitive sequence called 
spacers. In nature, they bound proto-spacer sequences providing a memory of 
past invasion. In this way, during invasion of bacteria, phage-derived spacers 
are inserted at one end of the locus, for the next immunization in the case of a 
subsequent attack. The CRISPR locus is flanked by CRISPR-associated genes 
(Cas) that encode protein components of the machinery (Cong et al., 2013). 
When CRISPR locus is activated, precursor crRNA is transcribed and then 
processed to produce crRNA mature, able to bound nucleic acid (Fig 9). 
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Fig 9 – CRISPR machinery. After foreign DNA infection, CRISPR array is activated and precursor crRNA 
transcripted. After its maturation, crRNAs bound Cas-proteins to became active and through the 
recognition of specific nucleotide sequences, bind and degrade DNA the invasor. 
 
For complex functioning is necessary crRNA, Cas9 endonuclease and tracRNA; it 
has been show that tracRNA, transcribed by the CRISPR array, is necessary for 
the stabilization of the structure and for its maturation. The target recognition 
by Cas9 protein requires a seed sequence within the crRNA and a protospacer-
adjacent motif (PAM) sequence upstream of the crRNA binding region. For the 
identification of target region by the mature crRNA it has been shown that is 
necessary and sufficient a 20bp sequence (Fig 10). 
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Fig 10 – Mechanism of action of CRISPR-Cas hybrid protein. A 20bp sequence in the target region is 
necessary and sufficient for the specific identification and binding of crRNA (green sequence). crRNA links 
a Cas9 nuclease (shown in violet), and after its activation it is able to cause doble-strand break in the 
region of interaction. tracrRNA links crRNA and is necessary for its stabilization. A PAM sequence (pink 
sequence) is necessary for the specificity of interaction. 
 
In vitro, the interference machinery can be mimed by co-delivering an 
optimized plasmid expressing Cas9 endonuclease and crRNA component; crRNA 
and tracr-RNA transcripts are fused together to form hybrid guideRNA (gRNA), 
the active and stabilized form of RNA molecule able to bind genome sequence. 
gRNA binds Cas9 protein, which is activated, and so the active complex, driven 
by the 20 bp DNA sequence complementary in the target region and the 
flanking PAM sequences, recognized by the Cas9 itself, causes double strand 
break in the target sequence (Cho et al., 2013b). It has been shown that the 
CRISPR-Cas system produces double strand break three nucleotides upstream 
of the PAM motif in the target region (Ding et al., 2013; Ding, 2013; Feng et 
al., 2013). According to this model, CRISPR-Cas system is able to target and 
cleave any DNA sequence, only by redesigning the gRNA (Gaj et al., 2013a). 
Besides, Cas9 proteins cleave target region only in presence of gRNA, and do 
not cleave a region that lacks the target sequence (Cho et al., 2013a). In vitro 
the CRISPR-Cas mediated genome editing has been applied to human (in 
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particular stem cells), zebrafish and bacterial cells. In addition, experiments 
conducted in parallel on human pluripotent stem cells by comparing CRISPR-
Cas9 system and TALEn system have shown that the efficiency of gene 
targeting for the first is higher than the second one (51-79% in CRISPR-Cas9 
system versus 0-34%). In mESC, transfection of a plasmid expressing both the 
optimized Cas9 protein and a gRNA targeting three Tet genes, has given 
excellent results: all clones tested carried mutations in genes with an efficiency 
of 65% up to 81%, and more than 20% of clones carried mutations in all six 
alleles. To test the potential of multiple gene targeting cells have been co-
trasfected with gRNAs simultaneously targeting five genes (including genes on 
Y chromosome); 10% of clones analyzed showed mutations in all five alleles 
(Wang et al., 2013). Excellent results have been obtained also in vivo: direct 
injection into fertilized egg of Cas9-mRNA and gRNA, targeting five genes, has 
shown an efficient production of mice bi-allelic mutated (around 80% of pups 
analyzed). Specific point mutations can also be obtained by giving a single-
stranded oligonucleotide donor with homology to the target region together 
with Cas9 and gRNA. In this way specific point mutations were simultaneously 
introduced in two different genes in 6/10 founders analyzed (Wang et al., 
2013). At the same time, the potential limit of the technique is the requirement 
for a N20-PAM target sequence that could limit site selection; and also the off-
target effects remain to be defined (Ding et al., 2013). 
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1.3.3. THE THIRD APPROACH: ARTIFICIAL 
CHROMOSOMES  
 
To overcome the problems highlighted by the use of viral or non-viral systems, 
as a means for gene therapy, the 90s have shown the development of methods 
characterized by low toxicity and high expression of hybrid genomic sequences 
within a target cell, such as the human artificial chromosomes (HACs). HACs, 
human artificial mini-chromosome, can be developed by using two different 
methods: the top-down (engineered chromosome) and the bottom up approach 
(de novo artificial chromosome). Both methods give rise to a functional 
chromosome that replicates and segregates independently from the genome of 
the cell in which is inserted, as a “normal” chromosome (Kazuki and Oshimura, 
2011; Larin and Mejia, 2002). 
The top-down approach is based on two different strategies: the telomere-
associated chromosome fragmentation and the radiation induced chromosome 
breakage. In the first approach, chromosome manipulation is generally done in 
intermediate host cells, and subsequently the chromosome of interest is 
transferred into a hybrid cell line by whole cell fusion; it’s important to have a 
selectable marker gene as close as possible to the centromere of mini-
chromosome for its subsequent selection. Different groups have used this 
methodology to insert into cells genomic sequences of interest. It was observed 
that within the HAC structure a well-defined insertion site for the exogenous 
gene of interest is necessary. One of the fundamental steps in the development 
of the methodology was reached in 2004 by Oshimura’s group, who built HAC 
21 pq telomere-directed breakage of human chromosome 21 in DT40 cells. 
Innovation was brought by the insertion of a loxP locus with a “neo” gene 
without the promoter in HAC structure, in this way any vector carrying a loxP 
site and a promoter can restore neomicine-expression by using the Cre-loxP 
system. This points out that by using this method it was possible to exploit the 
well-defined genomic structure of the carrier and a targeted insertion of the 
1.Introduction  
 
32 
 
transgene of interest using the loxP system, as well as to maintain the structure 
of mini-chromosome stable over time (Oshimura and Katoh, 2008). Using the 
HAC21 pq vector, various studies, based on the insertion of specific genes 
within the cell, such as the erythropoietin gene in human fibroblasts, or the 
mediation cell lineage-specific transgene expression, have been performed 
(Kakeda et al., 2005; Otsuki et al., 2005; Ren et al., 2005), and all applications 
have shown great versatility and functionality (Oshimura and Katoh, 2008). 
The bottom up approach is based on assembling an de novo chromosome by 
providing into the cells genomic sequences for its basic structure. Repeats of 
telomeric DNA sequence of a few hundred base pairs can generate de novo 
telomere at the end of the genome sequence. The bottom up approach was 
first demonstrated for the construction of yeast artificial chromosome (YAC) in 
Saccharomyces cerevisiae, and after that the technique was developed also in 
mammalian cells. For the first time in 1997 Willard group, by combination of 
synthetic human -satellite sequence, human telomeric DNA sequence and 
randomly shared human genomic DNA inserted in human fibrosarcoma HT180 
cells, achieved a stable exogenous mini-chromosome. Using this approach, the 
neo-formed chromosome ranges from 1 to 10 Mb in size and in the most cases 
is circular. It has been demonstrated the effectiveness of this vectors to vehicle 
sequences within the cell, such as the functional complementation of 
hypoxantine-guanine-phosphoribosyltransferase (HPRT) in human HPRT-
deficient cells (Grimes et al., 2001) or the formation of HAC de novo carrying 
the guanosine triphosphate cyclohydrolase I (Ikeno et al., 2002). In the 
bottom-up approach most criticisms concern the lack of control over the 
genomic sequence which is formed; in particular, the lack of a direct 
relationship between the DNA inserted into the cell and the HAC sequence both 
in terms of size and composition. It could also happens that the inserted DNA 
does not participate in the formation of artificial chromosome, but instead is 
inserted randomly in the cellular genome, and also often HACs contain a non-
predictable copy-number of gene of interest.  
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The use of chromosomal vector system shows different advantages, because 
they exist independently from the host genome and their inclusion does not 
involve insertional mutagenesis, can be transmitted to the progeny (in animal 
models) and can carry large genomic sequences including the regulatory 
regions. In fact, most eukaryotic genes are very large and their regulated 
expression often depends on genomic control elements; besides expression of 
most eukaryotic genes depend on the chromosomal environment in which they 
are positioned, and so engineered chromosomes might be used as an 
epigenetically regulated expression system.  
In the bottom up approach one of the most delicate step is the regeneration of 
a stable and functional centromeric sequence, because until a few years ago, 
the exact structure of the centromeric region was unknown; the first results 
obtained on yeasts were used to construct the mammalian artificial 
chromosome. Studies in rodent cells have highlighted how the efficiency of 
transfer rates in recipient cells is around to 10-5/10-4 (Kouprina et al., 2013). In 
both procedures to obtain an artificial chromosome, many advances have been 
made regarding their possible applicability as a carrier for gene therapy 
approaches, due to their safety and their ability to convey large molecules. For 
instance, gene therapy approaches for the replacement of dystrophin gene, the 
lack of which causes Duchenne muscular dystrophy, were conducted by 
conventional techniques, but have not led to good results because of the large 
size of the gene sequence; the use of HAC as a vector for the transport into 
diseased cells would be a safe and innovative approach that would exceed the 
size limit (Ren et al., 2006). Another important application of chromosome 
engineering technology is to generate animal model with aneuploidy syndrome 
to study the genetic basis of the disease and possible gene therapy approaches 
for their care (Oshimura and Katoh, 2008). 
The major limitation of HAC technique, however, remains the transfer method 
into the recipient cells of interest, because the conventional transfection 
approach is inappropriated.  
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The most common transfer method to introduce HAC vector into recipient cells 
is microcell-mediated chromosome transfer (MMCT).  
 
1.3.3.1.  Microcell-mediated chromosome transfer (MMCT) 
Microcell-mediated chromosome transfer (MMCT) is an approach to transfer 
whole or truncated chromosomes from a donor cell to a recipient one through 
microcell generation, their fusion with recipient cells and subsequent hybrid cell 
selection. MMCT allows the stable introduction of exogenous chromosomal 
material from a donor cell into a recipient cell, according to a cell fusion 
protocol. The technique was applied for the first time in the 70s, and since then 
many steps forward have been conducted to improve its protocol efficiency 
(Doherty and Fisher, 2003; Meaburn et al., 2005). The concept of chromosomal 
transfer is closely related to the concept of hybrid cell. Inter-specific somatic 
cell hybrids are obtained by the insertion in a somatic cell of one or more 
chromosomes belonging to another species, and have been used in several 
fields, one important example being the high resolution gene localization via 
radiation reduced cell hybrids. 
The first cell fusion experiments dates back to the 50s, when fusing agents 
such as Sendai virus, were used to mediate the fusion of cell membranes. In 
the same years the possibility of obtaining multinucleated cells using mitosis-
inhibiting substances, such as colchicine, was demonstrated. Multinucleated 
cells can be enucleated by using a cytochalasin B treatment and a subsequent 
centrifugation, in which the condensed chromosomes are "expelled" from the 
cell together with the nuclear and cell membrane, thus forming the micro-cells. 
Combining the protocols of multi-nucleation and whole cell fusion it has been 
possible to obtain hybrids each containing one or more chromosomes in 
addition to the normal karyotype structure of the recipient cell. At the end of 
the 70s the fusion of mouse microcells with human HeLa cells or Chinese 
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Hamster Ovary cells was reported, obtaining mouse-human and mouse-hamster 
hybrid chromosomal clones, respectively (Doherty and Fisher, 2003). 
The MMCT rationale procedure is simple: when a cell line is exposed to 
colchicine for a prolonged period in vitro, the number of metaphase cells 
increases and the nuclear membrane reorganizes itself around one or more 
chromosomes. Micronuclei so formed can be brought out the cells after 
centrifugation in the presence of Percoll (to obtain a gradient) and a 
microfilament disrupting agent such as cytochalasinB, and in this way they can 
be collected. The gradient separation is based on differences of densities of 
nucleus versus cytoplasm under centrifugal force. Once obtained, the 
micronuclei are filtered through membranes with pores of different sizes, to 
select microcell containing only one chromosome; generally, the crude microcell 
preparation is filtered using 8, 5 and 3 m nucleopore filters in sequence. Using 
this approach, only the smallest microcells, with complete elimination of whole 
cells and the 99% of karyoplasts, are obtained. These can be individually fused 
with a recipient cell which acquires the chromosome of interest, by using a 
fusogen agent, such as polyetilene glycol (PEG), that dissolves cell membranes, 
and phytohemagglutinin-P, that cause cell agglutination (Paulis, 2011) (Fig 
11). 
First of all, an heterokaryon is formed, a cell that contains nuclei from two 
different origins; after that, the fusion of the two nuclear membranes occurs 
and a single nucleus containing all the genetic material of the hybrid somatic 
cell, the synkaryon structure, is formed.  
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Fig 11 – Schematic representation of the MMCT protocol. Donor cell are exposed to colchicine in vitro for 
a prolonged period, then after Cytochalasin B treatment and centrifugation in a Percoll gradient, 
micronuclei are collected. They are fused with the recipient cell by using PEG and PHA-P to obtain hybrid 
cells. Clones containing different transferred chromosomes can be selected, to obtain only cells containing 
the chromosome of interest. 
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Two different methods for cell fusion, in suspension or in adhesion, can be 
used. The two protocols are similar but essentially revised according to the type 
of cells that are used. In the first protocol, the microcells preparation obtained 
is put in contact with the adherent cells, seeded at a specific density, and cell 
fusion is permitted through the use of fusogen agent that is added; in the 
second one this step is instead done in suspension after removal from the plate 
of both microcells and recipient cells (Killary and Lott, 1996). 
By using the MMCT protocol, different clones carrying the normal diploid 
chromosome number plus the chromosomes provided by the fused microcell 
can be obtained. The somatic hybrids that are formed in a wrong way or the 
microcells that remain adherent to cells without fusion are not viable in vitro 
applying a selection system, as explained here below.  
In fact, in order to follow the chromosome of interest during all the fusion 
steps, a marker gene, such as a resistance gene, which allows in vitro selection 
of the cell hybrids obtained, is needed. In this way hybrid cells grown under 
selective condition will survive only if they contain the preselected chromosome, 
in which the marker has been previously targeted to. For instance, the X 
chromosome, human 17 chromosome and mouse 11 chromosome can be easily 
selected by using the nucleotide salvage pathway complementation (HAT 
system). For other chromosomes, it is possible to insert a gene carrying the 
resistance for in vitro selection, such as the neo resistance. Generally, hybrid 
clones obtained retain the inserted chromosome as long as the selection 
medium is maintained in vitro.  
The main limitation is that not all cell lines are able to micro-nucleate, and 
among these there are many rodent cell lines, such as Mc-Lox and A9 lines, and 
human foreskin fibroblast in early passages. It was observed that the micro-
nucleation of many human lines is difficult, and in some cases the cells have 
low micro-nucleation efficiency and it is necessary to use a large amount of 
donor cells (Killary and Lott, 1996). 
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A normal donor cell line has to be fused with a cell line able to micronucleate, 
through a whole cell fusion, and a clone containing the desired chromosome is 
screened; this clone will be used for micronucleation. The whole cell fusion 
protocol is similar to that described previously. When two different cell-species 
are fused together, the resulting hybrid in vitro tends to lose preferentially most 
chromosomes of one of the two parental lines; for instance, in the 
human/rodent hybrid cells, most human chromosomes are generally eliminated. 
But it occurs that in some cases a single human chromosome is retained; in this 
way an inter-specific mono-chromosomal hybrid can be obtained (Paulis, 2011).  
Despite the rationale of the method is very straightforward, micro-cell mediated 
fusion is a technique rather complex to be carried out, due to the very low 
efficiency rate (10-4/10-6) (Kakeda et al., 2005; Katoh et al., 2004; Ren et al., 
2006). Different parameters may vary the efficiency of the protocol, including 
the concentration and the exposure time of colchicine, and the cell type of the 
donor line. Recently several methods have been studied in order to increase the 
efficiency of fusion in vitro, including the use of a lipid envelope of an 
inactivated hemagglutinating virus of Japan (HVJ), which has a function similar 
to PEG. It seems that this can increase the efficiency up to 3-8 times more 
(Kouprina et al., 2013). 
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1.4. LESCH-NYHAN SYNDROME 
Lesch Nyhan (LN) syndrome was described for the first time by M. Lesch and 
W. Nyhan in 1964, and is characterized by a deficiency of the activity of 
hypoxanthine-guanine phosphoribosyltransferase (HPRT) enzyme (Torres and 
Puig, 2007; Torres et al., 2012). The clinical signs of the disease occur a little 
time after birth, and one of the first clinical evidence in infants are orange 
crystal in the diapers or crystalluria with obstruction of the urinary tract. These 
symptoms are associated with renal failure and acidosis associated with 
vomiting, until the appearance of the first psychomotor disturbances at 3-6 
months of age, with delay in the sitting position and supporting the head, 
hypotonia and atetosic movements (Jinnah et al., 2006). Later, the 
manifestations of severe neurological disorders, mental retardation, a tendency 
to self-harm and hematological damage appear. In all patients with LN 
syndrome, the impairment of the pathway of purine metabolism causes an 
over-production of uric acid, which is associated to lithiasis and gout. 
Neurological damage can be manifested in rather different ways depending on 
the degree of enzyme deficiency present; there are, in fact, more mild forms of 
the disease that are defined Lesch-Nyhan variants, in which patients have only 
a partial deficiency of the enzyme (Torres et al., 2012). 
 
1.4.1. HPRT GENE AND MUTATIONS 
The disease is inherited as a recessive X-linked trait, in fact males are affected 
and women are generally asymptomatic carriers; the prevalence is 1/235.000-
380.000 live births. LN disease is due to mutations in the HPRT gene, localized 
on Xq.26 in humans. The homology of the human gene compared to the 
ortholog mouse gene is very high, around 95% for the coding regions, 
encoding proteins that differ in only 7 amino acids positions (Boyd et al., 2000). 
Genes localized on X chromosome, in fact, in species of eutherian mammals are 
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highly conserved, so a mutated gene that leads to genetic disease in humans 
can be studied in another mammalian species, including the mouse. Exploiting 
the high degree of homology of the two genomes, and the known genomic 
localization of some genes present on the entire length of X chromosome, a 
comparative phenotype map of human and mouse chromosome has been built, 
to highlight the high conservation of syntenic blocks during evolution. Already 
more than twenty years ago five conserved blocks have been identified. After 
that, a more detail analysis of the structure was done. (Blaschke and Rappold, 
1997). As now, twelve conserved segments in the chromosomal comparative 
map can be identified (Fig 12) (Boyd et al., 2000). Within a highly conserved 
region of the two genomes, is localized the HPRT locus.  
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Fig 12 – Comparative phenotype map between human and mouse. Each conserved block is identified by 
using a different color, and the order of loci inside the block is maintained. A total of twelve regions are 
recognized as highly conserved region in the comparative human-mouse map. HPRT locus (red arrow) is 
localized in one of the synthenic region.  
 
The HPRT gene is highly conserved both in its position that in the structure. 
The genomic organization of the human HPRT gene and its rodent homologous 
has been described (Kim et al., 1986; Melton et al., 1984). The mouse HPRT 
gene covers about 34 kb in length, while the human gene about 40kb, both 
consisting of 9 exons and 8 introns, and the overall arrangement is similar in 
both species (Baumstark-Khana et al., 2007) (Fig 13). Mouse and human HPRT 
protein show only eight differences, in that the conservation of the exons and 
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the length of the derived polypeptides are identical (218 amino-acids) 
(Baumstark-Khana et al., 2007; Konecki et al., 1982). 
 
 
Fig 13 – Gene structure of the human(up) and mouse (down) HPRT locus; both consisting of 9 exons and 
8 introns. The exons are indicated as black boxes and the locations and sizes of the introns of the gene (in 
kb) are indicated.  
 
The structural regulatory features are very similar to some of the regulatory 
signals common to a class of constitutive expressed "housekeeping" genes; in 
fact the protein is expressed in all tissues in different percentage, but generally 
at low levels (Kim et al., 1986). Numerous mutations in the protein have been 
identified, both in patients with LN syndrome and in patients with LN variants, 
among which the most common are point mutations and deletions (Tab 2). 
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Tab 2 - List of the most common mutations in patients suffering from LN and LN variants.  
 
1.4.2. HPRT FUNCTIONS 
HPRT gene has been detected in all somatic tissues at low levels (0.005-0.01% 
of total mRNA), and has showed significantly higher levels in the central 
nervous system (0.02-0.04%). The enzyme is involved in the salvage pathway 
of purine (Stout and Caskey, 1985). The synthesis of purines (adenine and 
guanine) and pyrimidines (timine and cytosine) in the life cycle of a cell is a 
critical step, since these molecules are the basis of the structure of nucleic 
acids, and are also involved as coenzymes in metabolic reactions. Most 
organisms are able to synthesize de novo both purines and pyrimidines, but 
when endogenous purines and pyrimidines are available, the "salvage pathway” 
to obtain new nucleosides is preferred. It was observed that almost 90% of free 
purines in humans are recycled, thus preserving as much as possible the energy 
of the cell. In fact, the classical de novo synthesis pathway is much expensive 
for the cell, since several enzymatic steps need to be performed to obtain 
inosinate (IMP) from ribose-5-P. Using the salvage pathway, instead, is possible 
to reuse the bases that are released constantly from the metabolic degradation 
of the nucleotides in the cell. Guanine and hypoxanthine (the deamination 
product of adenine) are recovered through its unique transferase reaction 
catalyzed by HPRT protein. Hypoxantine is modified to IMP that is able to give 
rise, according two different pathways, adenilate (AMP) e guanilate (GMP). On 
the other hand, guanine can be converted directly to GMP (Torres and Puig, 
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2007). In both cases, phosphoribosyl-pyrophosphate (PRPP) molecule has to be 
used as co-substrate (Fig 14).  
 
 
Fig 14 – A simplified overview of the pathways of purine salvage pathway. HPRT enzyme catalyzes the 
recovery of hypoxanthine and guanine to form respectively IMP and GMP. On the other hand, an 
accumulation of hypoxanthine and guanine causes the over-production of uric acid. 
 
When the HPRT enzyme is not available, however, an accumulation of 
precursors occurs, causing over-production of xanthine, whose oxidation 
produces uric acid. In the brain the purine salvage pathway catalyzed by HPRT 
is particularly important, for this reason much of the damage that can be 
observed in patients with LN syndrome are dependent on the nervous system.  
HPRT enzyme functionality in vitro can be tested using the HAT selection 
medium. HAT selective medium (hypoxanthine-aminopterin-thymidine medium) 
was developed for the first time by Littlefield in 1964, and is a selective medium 
for mammalian cell culture, composed by the combination of aminopterin, a 
drug that acts as a folate metabolism inhibitor by inhibiting dihydrofolate 
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reductase, and hypoxanthine and thymidine, which are intermediates in DNA 
synthesis (Bartal et al., 1987; Ege, 1984). Aminopterin blocks the DNA de novo 
pathway, but at the same time hypoxanthine and thymidine provide cells with 
intermediates for the activation of the "salvage pathway". In this way it is 
possible to select HAT resistant cells that do not carry mutations in the HPRT 
gene, as they can use the salvage pathway in the normal cell duplication. 
Conversely, HPRT negative cells can be selected in 6-thioguanine (6-TG). 6-TG 
belongs to the thiopurine family of drugs which are examples of 
antimetabolites. It is a purine analogue of the base guanine; cells lacking HPRT 
are resistant to 6-thioguanine (6-TG) and 8-azaguanine. In this way can be 
selected only the cell population carrying the HPRT gene deletion. 
 
1.4.3. THERAPY 
LN syndrome does not have efficient care yet. The production of uric acid using 
allopurinol can be controlled; this compound blocks the synthesis route, 
although it has not produced any improvement in behavior and neurological 
disorders. In addition, the lack of precise knowledge of the dysfunctions at the 
neurological level has precluded the development of optimal treatment. On the 
other hand, about the behavioral manifestations, it is possible to use physical 
restraints and pharmaceutical treatments (Torres et al., 2007). Many research 
groups have attempted to find a cure for this disease; LN syndrome, being a 
hereditary genetic disease, has often been the field of gene therapy 
approaches. Unfortunately, to date no clinically relevant results have been 
obtained there (McCarthy, 2004).  
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Several approaches to the correction of genetic defects have been investigated 
in the last two decades, including those based on viral vectors. Although viral 
vectors are a powerful instrument for gene therapy and are being used in 
human trials, they present drawbacks such as risk of insertional mutagenesis 
and limited insert size. Homologous recombination techniques, which has long 
been applied to mouse stem cell engineering, have recently been used in 
combination with novel tools exploiting the activity of nucleases coupled to 
targeting methods such those based on zinc fingers, TALE and CRISPR, which 
allow targeting to specific DNA sequences to a great extent. However some 
genetic defects, and in particular genomic abnormalities such as large deletions, 
are not suitable to correction with these tools. Here I suggest that large 
structural abnormalities of the X chromosome can be treated by chromosome 
transfer mediated by microcells (MMCT). The rationale underlying my work was 
the fact that by MMCT all the sequences and structures needed for proper 
expression of the affected gene(s) are transferred into the defective cell. 
Furthermore, additional X chromosomes are usually silenced and cells with 
more than two X chromosomes are essentially normal, as shown by XXX 
trisomic human organisms. 
 
Hence, the aims of the present work are: 
1. To define conditions for the MMCT of entire murine X chromosomes into 
embryonic stem cells 
 
1.1 generation of the donor cell line containing a normal X chromosome 
1.2 choice of the recipient ESC line with an X-linked genetic defect 
1.3 definition of the best experimental conditions for MMCT 
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2. To analyze the clones containing a single additional X chromosome 
 
2.1 demonstration of the correction of the genetic defect (HPRT negative, 
Lesch-Nyhan syndrome) in selected clones 
2.2 analysis of X chromosome linked SNP to confirm chromosome transfer 
2.3 analysis of the genome stability 
2.4 analysis of the pluripotency 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
3. EXPERIMENTAL PROCEDURES 
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3.1. CELL CULTURES  
 
HM1 is a mouse embryonic stem cell line (mES) from 129/Ola mouse 
strain(Hooper et al., 1987; Magin et al., 1992) lacking the HPRT enzyme. This 
defect prevents its growth in the selective HAT (hypoxanthine 100 uM, 
aminopterin 0.4 ug/ml and thymidine 16 uM) medium (SIGMA). The embryonic 
stem cell line was bought from Open Biosystem. The HM1 cell line and the 
derivative hybrid clones were cultured in 7% CO2 at 37°C on mitomycin-C 
(SIGMA) treated MEF feeder layer in standard ESC media.  
 
The A9 mouse fibroblast line was derived by Littlefield (Littlefield et al. 1964) 
from the L cell strain by selection for resistance to 8-azaguanine, since it also 
lacks the enzyme hypoxanthine-guaninephosphoribosyltransferase (HPRT). For 
the same reason A9 cells do not grow in HAT selective medium.  
 
MEFs were obtained by mincing and dissociating 13.5 days post coitum (dpc) 
CD-1 embryos (Charles River Laboratories) by Trypsin-Versene (Lonza); primary 
cultures were maintained in DMEM medium (Lonza) supplemented with 10% 
fetal calf serum (Lonza) and incubated at 37°C with 5% CO2. 
 
C12 and B1 are somatic hybrids obtained by cell fusion between A9 cells and 
MEF cells. The cell lines are maintained by standard culture procedures in 
DMEM medium (Lonza), supplemented with 10% fetal calf serum (Lonza) and 
HAT selective medium (SIGMA), and incubated at 37°C with 5% CO2.  
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3.2. WHOLE CELL FUSION AND COLONY 
ISOLATION 
 
MEF cells and mouse A9 cells were fused according to the subsequent protocol. 
A total suspension of 2x106 MEF and A9 cells (1:1) were mixed together. After 
centrifugation (160g), 1 ml of a pre-warmed solution of 50% polyethylene 
glycol (PEG) (Roche) was poured onto the cell pellet over 1 min and mixed for 
two minutes. 10 ml of fresh complete medium were then gradually added to the 
cell suspension over 10 min; the diluted suspension was distributed in three 
100 mm Petri dishes and incubated at 37°C with 5% CO2. The cells were 
maintained in nonselective medium for 24 hr and then trypsinized and split into 
ten 100 mm Petri dishes in HAT1x selective medium. Hybrid clones were 
individually picked, culture expanded and stored; after the analysis, one of 
them used as donor cells in the microcell mediated chromosome transfer 
protocol. We have chosen for the subsequent protocol C12 A9/MEF clone; the 
presence of a normal whole X chromosome was demonstrated by molecular 
and cytogenetic analysis.  
 
 
3.3. MICROCELL MEDIATED CHROMOSOME 
TRANSFER (MMCT) AND COLONY 
ISOLATION 
 
The C12 A9/MEF hybrid clone, containing a normal X chromosome, was used as 
source of microcells for the MMCT. C12 cell were seeded and, after reaching 
80% of confluence, treated with 0.06 g/ml of colcemid (KaryoMAX - Life 
technologies), to induce the formation of micronuclei. After 48 h of incubation 
the cells were trypsinized, and microcells separated by cytochalasin B digestion 
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(10 g/ml, SIGMA) in a Percoll gradient centrifugation. After centrifugation at 
16.000g for 70min at 36°C, the isolated microcells were suspended in 12 ml of 
serum-free DMEM and filtered sequentially through 8 m and 5 m 
polycarbonate filters (Millipore). The purified microcells were collected by 
centrifugation at 400g for 10min, suspended in 2 ml of serum-free DMEM 
containing 100 g/ml of phytohemagglutinin (PHA, SIGMA) and then mixed 
with an equal amount of mES monodispersed cells. The obtained microcells 
were fused with HM1 mouse ES unsynchronised cells. 
After centrifugation at 160g, 1 ml of a pre-warmed solution of 50% PEG 
(Roche) was poured onto the cell pellet over 1 min, followed by extensive 
washing in serum free DMEM. After the cell fusion, cells were seeded on a 
mytomicine-C arrested feeder layer. The cells were maintained in non-selective 
medium for 24 hr at 37°C in 7% CO2, then trypsinized and split into ten 60 mm 
Petri dishes containing ES medium supplied with HAT 1x. 
 
 
3.4. CHROMOSOME AND KARYOTYPE 
ANALYSIS 
Chromosome analysis was done both on slide preparations and in suspensions. 
Briefly, cell cultures were treated with colcemid (KaryoMAX - Life Thecnologies) 
at a final concentration of 0.1 g/ml for 2h at 37°C, and then mitoses were 
mechanically removed. After hypotonic treatment with 0.075 M KCl and fixation 
in methanol:acetic acid (3:1 v/v), the cell suspension was dropped onto a slide 
and air dried. For slide preparation the procedure was the same. Chromosome 
counts and karyotype analyses were done on metaphases stained with 
Vectashield mounting medium with DAPI (Vector laboratories) for G-banding 
analysis. For the analysis an Olympus BX61 Research Microscope equipped with 
a cooled CCD camera was used. Images were captured and analyzed with 
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Applied Imaging Software CytoVision (CytoVision Master System with 
Karyotyping & FISH). 
 
 
 
3.5. FLUORESCENCE IN SITU 
HYBRIDIZATION (FISH) 
 
Whole mouse X chromosome paint was used as DNA probe for fluorescence in 
situ hybridization experiments. The probe was obtained labelling X flow-sorted 
DNA chromosome with degenerate oligonucleotide primed polymerase chain 
reaction (DOP-PCR) using Spectrum Orange-dUTP (Vysis) (Darouich et al., 
2012). The labelled probe was suspended in hybridization buffer (50% 
formamide, 10% dextran sulphate, 1x Denhart’s solution, 0.1% SDS, 40 mM 
Na2HPO4 pH 6.8, 2xSSC) containing a 10x excess of Cot1 DNA (Life 
Technologies); denatured at 80°C for 10 min and pre-annealed at 37° for 30 
min. Slides were treated with Pepsin (0.004%) in 0.01 M HCl at 37°C for 2-3 
min, washed in PBS, PBS/MgCl2 and subsequently placed in 1% 
Formaldehyde/1XPBS/MgCl2 for 10 min. Finally, slides were dehydrated through 
the ethanol series before denaturation in 70% formamide/2xSSC. Hybridization 
was done overnight at 37°C in a wet chamber. Stringent washings were done in 
50% formamide/2xSSC at 42°C. Slides were mounted in Vectashield mounting 
medium with DAPI (Vector laboratories) and then scored under an Olympus 
BX61 Research Microscope equipped with a cooled CCD camera. Images were 
captured and analyzed with Applied Imaging Software CytoVision (CytoVision 
Master System with Karyotyping & FISH). 
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3.6. MULTICOLOR- FISH (M-FISH) 
The multicolor-FISH (M-FISH) hybridization procedure follows standard FISH 
protocol with an emphasis on sample preparation. M-FISH was performed using 
mouse SKY paint probe mixtures (Applied Spectral Imaging, Santa Clara, CA) 
according to the manufacturer’s protocol. The mix probe is shown in the Tab 3. 
. 
 
 
Tab 3 - SkyPaint probe mixture combination (Applied Spectral Imaging, Santa Clara, CA). On the top of 
the table is shown, for each fluorocrome used, the wavelenght (nm) of emission and absorption spectrum. 
Each fluorocrome is indicated using a letter. On the bottom of the table is shown the fluorocromes 
combination specific for each mouse chromosome.  
 
Slide preparation was performed as previously described for the FISH 
procedure. Hybridization was done at 37°C in a wet chamber for 24-36hr. 
Stringent washings were done in 0.4XSSC at 72°C for 5min. After the blocking 
solution two antibodies incubations were done, Cy5 staining reagent and Cy5.5 
staining reagent. Finally, slides were mounted in Vectashield mounting medium 
with DAPI (Vector Laboratories) and then scored under an Olympus BX61 
Research Microscope equipped with a cooled CCD camera. Images were 
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captured and analyzed with Applied Imaging Software CytoVision (CytoVision 
Master System with mFISH). 
 
 
3.7. IMMUNOFLUORESCENT ASSAY 
For immunostainings, cells were seeded on a mitomycin-C inactivated MEF and, 
reached the optimal confluence, fixed with 4% PFA for 10min at room 
temperature, then washed with PBS and permeabilized in 0.3% triton X-100 in 
PBS for 10min at room temperature.  
After blocking incubation using ES-FBS, primary antibodies used were anti Oct4 
(Abcam, ab18976), anti Nanog (Novus Biologicals), anti Sox2 (Abcam, 
ab97959), anti SSEA1 (Cell signaling Technologies, MC480). The primary 
antibodies incubation was done overnight. Then samples were washed with PBS 
and incubated with secondary Alexa Fluor®488-coniugated antibodies (Life 
technologies), diluted 1:2000 in blocking solution. Samples were counterstained 
with h 4'-6-Diamidino-2-phenylindole (DAPI) 200 µg/ml (Life Technologies) and 
mounted. Slides were observed using an Olympus BX61 Research Microscope 
equipped with a cooled CCD camera. Images were captured and analyzed with 
Applied Imaging Software CytoVision (CytoVision Master System). 
 
 
3.8. ALKALINE PHOSPHATASE (AP) 
For alkaline phosphatase activity tests, ES HM1 or ES hybrid cells were seeded 
on a mytomicine-C inactivated MEF and used at achievement of 80% of 
confluence. The tests were conducted using Alkaline Phosphatase kit (SIGMA-
ALDRICH) according the manufacturer’s recommendations. Slides were scored 
under an inverted IX53 Microscope. 
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3.9. REVERSE TRANSCRIPTION-PCR (RT-
PCR)  
First-strand cDNAs were synthesized directly from ES HM1 and ES “hybrid” 
cells, using the High Capacity cDNA Reverse Transcription Kit (Applied 
Biosystem) according to the protocol provided by the supplier. PCRs were 
performed using specific primer pairs (Tab 4). 
 
Tab 4 - Primer sequences for each pluripotency markers analyzed, and for GAPDH positive control, 
performed by reverse-transcription PCR. It is shown the nucleotide sequence for both forward and reverse 
primers, and also the length of bands obtained.  
 
PCR reactions were performed under the following conditions: initial denaturing 
step for 5min at 94°C, denaturing for 30s at 94°C, annealing temperature for 
30s, extension for 30s at 72°C, repeated 30 times; final extension for 10min at 
72°C. The PCR products were visualized on 1.5% agarose gel electrophoresis 
stained with ethidium bromide or gel-red staining. 
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3.10. TERATOMA FORMATION AND 
HISTOLOGY 
To produce teratomas, 2x106 ES HM1 or ES hybrid cells were inoculated 
subcutaneously into the flank of six-week-old CD-1 (ICR)-nu mice (Charles 
River Laboratories). After 2-3 weeks resected teratomas were fixed in 4% PFA 
and processed for paraffin sectioning, then samples were stained with 
hematoxylin and eosin (H&E). Histological analyses of the samples were 
performed by Dr. C. Recordati and Prof. E. Scanziani, Mouse & Animal 
Pathology Laboratory (MAPLab) Animal Model Systems - FONDAZIONE 
FILARETE. 
 
 
3.11. GENOME SNPs 
SNPs were analyzed by the polymerase chain reaction (PCR) using specific 
primers to each genome sequence. We relied on the NCBI database 
(http://www.ncbi.nlm.nih.gov/projects/SNP/MouseSNP.cgi), for appropriate 
choice of primers pairs ( Tab 5).  
 
Tab 5 - Primer sequences for each X-chromosome SNP analyzed and for the HPRT locus. It is indicated 
the nucleotide sequence for both forward and reverse primers, and also the dimension (in bp) of band 
obtained by using PCR assay. 
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For the analysis of the HPRT locus the same reverse primer for both WT and 
delete allele and a specific forward primer for each allele have been used 
(McEwan and Melton, 2003); DNA of hybrid clones and parental cells was 
extracted with GenElute™ Mammalian Genomic DNA Miniprep Kit (SIGMA) 
according to manufacturer’s recommendations. 
PCR reactions were performed under the following conditions: initial denaturing 
step for 5min at 94°C, denaturing for 30s at 94°C, annealing temperature for 
30s, extension for 30s at 72°C, repeated 30 times; and final extension step for 
10min at 72°C. The PCR products were visualized on 1.5% agarose gel 
electrophoresis stained with ethidium bromide or gel-Red staining. For 
sequencing, PCR products were recovered using Wizard SV Gel and PCR Clean-
Up System (Promega) and sequenced with specific F primer. 
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4.1. RECIPIENT EMBRYONIC and DONOR 
CELL LINES 
The cell line we selected as recipient cell line, to perform microcell-mediated 
chromosome transfer (MMCT) protocol, was mouse HM1 embryonic stem cell 
line. HM1 cell line was purchased from OpenBiosystem, and we have confirmed 
the pluripotency of cells with the classical tests in vitro. The presence of alkaline 
phosphatase activity in HM1 cell line as first test was proved, as shown in Fig 
15. Mouse HM1 cell line showed positivity.  
 
 
Fig 15 - Alkaline phosphatase activity in HM1 cell line. HM1 cells (positive clones) are seeded on MEF 
feeder layer (negative cells). 4x magnification, scale bar 200 m. 
 
To prove chromosome stability in vitro, we characterized HM1 cell line with 
cytogenetic analysis according the Q banding (DAPI staining). We analyzed 30 
metaphases, of which 84% had a chromosomal distribution of 2n=40 (Fig 16). 
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Fig 16 - Chromosomal distribution of the mouse HM1 embryonic stem cell. In the analysis 30 metaphases 
were tested. The median chromosome distribution was 2n=40. 
 
We investigated also the karyotype, and any chromosomal rearrangements was 
detected, as shown in Fig 17 , using a classical Q- banding karyotype. 
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Fig17 - Karyotype analysis of the HM1 embryonic stem cells. The image is representative of a Q-banded 
karyotype, using DAPI reagent. No rearrangement was detected using the classical DAPI banding. 
 
To show the stemness of the cell line, the classical plurypotency markers 
Nanog, OCT4 and SOX-2 were analyzed using reverse transcription-PCR (RT-
PCR) and immunofluorescence assays. In the RT-PCR assay we used cDNA of 
E14tg2a cell line as positive control; HM1 parental line showed a gene 
expression comparable to the positive control (Fig 18).  
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Fig 18 - RT-PCR analysis of pluripotency markers in the HM1 cell line. We tested cDNA of HM1 cell line 
and cDNA of E14tg2a cell line, used as positive control. Housekeeping GAPDH, Nanog (top), OCT4 and 
SOX-2 (bottom) cDNAs were analyzed. HM1 cell line showed an expression comparable to the positive 
control for all markers analyzed. To the left of each marker the size (bp) of the amplified band is indicated.  
 
In the immunofluorescent assay we tested the most common pluripotency 
markers Nanog, Oct4, SSEA-1 and SOX-2; all markers analyzed were expressed 
(Fig 19).  
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Fig 19 - Immunofluorescence assay of pluripotency markers in the HM1 cell line. Oct4, Nanog, Sox-2 and 
SSEA-1 markers were tested; in each image are visible clones stained with an anti-Oct4, anti-Nanog, anti-
Sox-2 and anti-SSEA-1 antibody (green fluorescent signals), counterstained with DAPI (blue). All markers 
showed clear positivity.  
 
As X chromosome donor we used an A9/MEF hybrid cell line generated de 
novo. To this aim, we started with the A9 murine fibroblast cell line that is an 
HPRT mouse defective cell line, which easily micro-nucleates and has previously 
been used to transfer single chromosomes (Kugoh et al., 1999). The A9 cell line 
has a modal number of 52 chromosomes; range between 46 to 54 
chromosomes, and is a hyperdiploid cell line with 24 to 26 marker 
chromosomes common to all cells; structurally normal chromosomes 4, 15, 16, 
17, 18 and X are absent. We analyzed the A9 cell line to investigate the 
chromosome pattern in culture. As can be observed in the Tab 6, the median 
chromosome distribution is 56, counting 20 biarmed chromosomes, resulting 
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from the centromeric fusion of acrocentric chromosomes, 35 telocentric 
chromosomes and two dot-like structures.  
 
 
Ch. BIARMED Ch. TELOCENTRIC DOT-LIKE Ch. TOTAL 
A9 cell line 20 35 2 56 
 
Tab 6 - Chromosomal characterization of the A9 cell line in culture. In each metaphase the number of 
chromosomes was counted, and the chromosome median for each class is shown: biarmed chromosomes, 
telocentric chromosomes and dot-like structures.  
 
Since this line is defective for the HPRT gene, successful normal X chromosome 
transfer, bearing a normal HPRT gene, can be selected in HAT medium. To 
prove that, we maintained A9 cells in HAT selection medium, and the cells died; 
in addition, FISH experiments with a mouse X chromosome probe confirmed 
the absence of a normal single X chromosome (Fig 20).  
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Fig 20 - FISH image of metaphase spreads prepared from the A9 cell line, performed with mouse X 
chromosome paint labeled with Spectrum Orange (red), and counterstained with DAPI (blue) (merge on 
the right). DAPI-stained chromosomes were converted into a black and white image (on the left). No 
whole normal X chromosome can be observed. Magnification 60x 
 
MEF pool was obtained by sacrificing at day 13.5 a healthy female CD1 
pregnant mouse and recovering embryos to obtain a primary line of fibroblasts 
(MEF), which were cultured and collected in a pool of cells. It is important to 
note that this pool was composed by XX and XY cells, derived from different 
embryos, each carrying one (male embryos) or two (female embryos) normal X 
chromosomes.  
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4.2. GENERATION OF THE A9 HYBRID CELL 
LINE WITH A NORMAL X CHROMOSOME 
BY WHOLE CELL FUSION 
 
We performed a whole cell fusion protocol to obtain A9/MEF hybrid clones, able 
to micro-nucleate, to have a donor cell line carrying a normal mouse X 
chromosome. A9 cells were fused with MEF pool cells. In the whole-cell fusion 
protocol, two million MEF and A9 cells in a 1:1 ratio were fused together in 
suspension using a PEG fusogen (1 minute). The cells were then re-plated using 
A9 complete medium and the HAT selection was added the following day. 
Seven clones were obtained, grown separately and always maintained in 
selective medium, to avoid any possible contamination of whole A9 cells. A 
chromosomal distribution of every clone has been performed as first analysis. 
In the Tab 7 the median chromosome distribution for all clones is shown, 
classifying them as biarmed chromosomes, telocentric chromosomes and dot-
like structures.  
          
CLONE Ch. BIARMED Ch. TELOCENTRIC DOT-LIKE Ch. TOTAL 
C12 22 67 1 90 
D2 23 48 2 73 
B1 22 52 1 76 
C9 18 49 2 67 
C11 23 48 2 73 
G9 24 45 3 72 
A9 20 35 2 56 
 
 
Tab 7 - Chromosomal characterization of A9/MEF hybrid clones obtained after whole cell fusion. In each 
metaphase the number of chromosomes was counted, and the chromosome median is shown, classifying 
them in biarmed chromosomes, telocentric chromosomes and dot-like structures.  
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To identify among the clones obtained the best ones for our purpose, we 
performed FISH experiments on chromosome preparations obtained from 
individual clones, using an X chromosome paint probe. We identified two 
clones, C12 and B1, on which FISH experiments revealed the presence of at 
least one normal whole X chromosome. In particular, while in the C12 hybrid 
clone only one normal X chromosome was identified, in B1 clone two normal X 
chromosomes were detected. We analyzed 30 metaphases for each FISH 
experiment, and a representative image per each clone is shown in the Fig 21. 
 
 
Fig 21 - FISH experiment on metaphase spreads prepared from B1 A9/MEF (on the right) and C12 
A9/MEF clones (on the left), performed with a mouse X chromosome paint probe labeled with Spectrum 
Orange (red) counterstained with DAPI (blue) (merge on the bottom). Every DAPI-stained methaphase 
was converted into a black and white image (top). In B1 clone two X chromosomes can be visualized, 
while in clone C12 only one normal chromosome can be detected, beyond those rearranged already 
present in the starting A9 cell line. Magnification 60X. 
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The presence of an active HPRT gene was demonstrated through the survival 
C12 and B1 clones in HAT selection medium.  
 
4.3. MMCT FUSION 
Microcell-mediated chromosome transfer (MMCT) experiment was done 
according to the method described in Experimental Procedures. The hybrid C12 
clone was chosen because it showed a better ability to micronucleate. The C12 
clone, reached the 80% of confluence, was treated with 0.06 g/ml colcemid, 
to induce the formation of micronuclei. After 48 h incubation, the microcells 
were isolated by cytochalasin B digestion (10 g/ml) and Percoll centrifugation 
(5*107 microcells were counted). After centrifugation, the isolated microcells 
were filtered sequentially through 8 m and 5 m polycarbonate filters and 
after this step 1.6*107 single microcells were collected. The purified microcells 
were suspended in DMEM containing 100 g/ml of phytohemagglutinin (PHA) 
and then mixed with an equal amount of parental HM1 monodispersed cells. 
After centrifugation a pre-warmed solution of 50% PEG (Roche) was poured 
onto the cell pellet over 1 min, followed by extensive washing in serum free 
DMEM. The cell suspension was seeded on mitotically inactivated fibroblasts. 
The day after fusion, HAT 1x selective medium was added and after two weeks 
two clones were obtained, grown in selection medium and individually 
expanded in culture for the subsequent analysis.  
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4.4. GENERATION AND ANALYSIS OF 
CORRECTED CLONES BY MMCT  
To prove the insertion of a normal X chromosome in the mouse recipient cell 
line, chromosome distribution of both HAT-resistant clones was performed. We 
analyzed 30 metaphases for both MMCT clones, and both showed a 
chromosome distribution of 2n=41 (Fig 22 A, B). The HPRT gene PCR 
amplification (Fig 22 C), performed on HM1 cl8 and cl1, showed the presence 
of both the normal (746 nt band) and the mutated (628 nt band) HPRT allele, 
confirming that a wild-type copy of the gene from the normal X chromosome 
has been acquired.  
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B  
C   
Fig 22 - Chromosomal distribution and genomic PCR analysis performed on HM1 cl8 and cl1. 
Chromosomal distribution of HM1 cl1 (A) and HM1 cl8 (B), performed at low passages in vitro. Both clones 
showed a median chromosome distribution of 2n=41. HPRT gene PCR amplification (C) showed the 
presence of both normal and mutated alleles in MMCT clones obtained, due to the transfer of the wild-
type copy of gene within the normal X MEF chromosome. In the HM1 parental line only the HPRT mutated 
allele is present, while in the MEF donor cells only the HPRT wild-type allele is shown.  
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4.4.1. GENOME STABILITY OF THE OBTAINED 
CLONES  
The two MMCT clones were maintained in culture for three weeks. Whereas 
HM1 cl1 had a propensity to return to a chromosome distribution of 2n=40 (Fig 
23 A), the HM1 cl8 showed a more stable pattern, maintaining the 
chromosomal distribution of 2n=41 (Fig 23 B). 
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B  
Fig 23 - HM1 cl1 and cl8 chromosome distribution at different passages in vitro. HM1 cl1 (A) showed an 
unstable chromosome pattern after several in vitro passages, changing from 2n=41 to 2n=40. HM1 cl8 
(B) showed a more stable pattern, maintaining the chromosomal distribution of 2n=41.  
 
We therefore decided to use HM1 hybrid cl8 because it seemed more stable, 
and we continued the analysis. To follow the trend of the clone in vitro we 
repeated distribution chromosome analysis at different steps, and even at 
increased passages the clone showed a stable chromosome distribution. We 
have also tested the chromosomal stability in vitro after adding and removing 
the HAT selective medium, and also in this case the clone kept its original 
distribution of 2n= 41 chromosomes (Fig 24).  
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Fig 24 - HM1 cl8 chromosome distribution after adding and removing HAT selective medium. The clone 
has been cultured for seven passages in HAT selective medium, then for three passages without selective 
medium and finally the HAT medium was re-added in culture. The median chromosome distribution 
remained stable at 2n= 41. 
 
4.4.2. HM1 CL8 CHARACTERIZATION  
4.4.2.1. Molecular analysis 
To further demonstrate the MEF X chromosome transfer into the mouse HM1 hybrid 
cl8, SNP analysis of X chromosome was performed. We have used the SNPs mouse 
database of NCBI (http://www.ncbi.nlm.nih.gov/projects/SNP/MouseSNP.cgi), for the X 
chromosome, where the C57 strain is reported. Since the HM1 parental cell line derived 
from 129/Ola strain, while the MEF donor cell line derived from the CD1 strain, we 
chose some informative SNPs for our purpose, that are those in which the nucleotide 
sequence is different in the two strains. In this way it is possible to distinguish the 
donor X from the HM1 parental chromosome. We have tested several SNPs by PCR 
analysis of HM1 and MEF genome, and four informative SNPs were found; then, PCR 
amplification and sequence analysis were performed. As shown in the Tab 8, analyzing 
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HM1 cl8 genome, both the endogenous and exogenous SNPs X chromosomes were 
present.  
 
Tab 8 - Informative SNPs of the X chromosome. In addition to the HPRT gene, four informative SNPs 
were found as different between the 129/Ola and CD1 parental strains used. For each SNPs is indicated 
the position (top) and the specific nucleotide polymorphism of HM1 129/Ola, MEF and HM1 cl8. As the 
hybrid HM1 cl8 has two X chromosomes, each derived from the two original strains, it shows the presence 
of both nucleotides. In rs3166628 and rs8251054 SNPs, in addition to the published in the database, we 
found two additional polymorphisms within the amplified region in the first region, and one in the second 
amplified genomic region. 
 
4.4.2.2. Cytogenetic analysis 
Analyzing the clone 8 karyotype, no obvious rearrangements was identifiable by 
the classic Q- banding DAPI, as shown in Fig 25. The karyotype of 20 
metaphases was analyzed, and the analysis pointed out that the all autosomes 
and sex chromosomes were normal in number and structure and that there 
were no rearrangement or aneuploidy detected by the classic DAPI banding. 
Compared to the parental HM1 cell line, only a normal X chromosome was 
inserted.  
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Fig 25 - HM1 cl8 karyotype. The image is representative of Q-banded karyotype, obtaining using DAPI 
staining. No detectable rearrangements or aneuploidy are visible. 
 
To avoid the possibility of rearrangements involving X chromosome, and to 
confirm the presence of two whole and normal X chromosomes in HM1 cl8, 
FISH experiments were carried out, using mouse chromosome X paint probes. 
30 metaphases were analyzed, and as shown in Fig 26, FISH analysis detected 
in hybrid cl8 signals originating only from two structurally normal X 
chromosomes, demonstrating that the MMCT procedure did not cause any 
rearrangements of the original and transferred X chromosome.  
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Fig 26 - FISH experiment on metaphase spreads prepared from HM1 cl8 p5, performed with mouse X 
chromosome paint labeled with Spectrum Orange (red) counterstained with DAPI (blue)(merge on the 
right). Every DAPI-stained methaphase was converted into a black and white image (on the left). Two 
normal X chromosomes can be visualized. Magnification 60x. 
 
To confirm the absence of rearrangements or aneuploidy both in the autosomes 
and the sex chromosomes after in vitro manipulation experiments, a multicolor-
FISH (M-FISH) was performed. M-FISH uses a pool of whole-chromosome 
painting probes with different fluorochromes combinations that result in specific 
color patterns for each chromosome. M-FISH experiments were performed by 
using Applied Spectral Image (ASI) probes as described in Experimental 
Procedure. Again, no chromosomal rearrangements were identified (Fig 27). In 
conclusion, HM1 cl8 can be considered to have acquired an additional, HPRT 
positive, chromosome without any rearrangement of the original chromosome 
pattern.  
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Fig 27 - M-FISH analysis on metaphase spreads prepared from HM1 cl8, performed with Applied Spectral 
Image kit probes (ASI). The karyotype is shown in inverted DAPI-banded (left), and in the pseudocolor 
image (on the bottom). The hybridization signal is visible on the upper part of panel (right). Analyzing 
karyotype, no rearrangement can be noted.  
 
4.4.2.3. Stemness 
To analyze the pluripotency of the hybrid cl8 obtained, alkaline phosphatase 
activity was tested (Fig 28); as expected the clone retained the enzymatic 
activity as well as the parental HM1 cell line.  
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Fig 28 - Alkaline phosphatase activity in HM1 cl8 hybrid line. Cl8 cells (positive clones) are seeded on MEF 
feeder layer (negative). The hybrid clone retained the enzymatic activity as well as the parental HM1 cell 
line. Magnification 4x, scale bar 200 m 
 
In addition, immunofluorescence assays for the classical pluripotency markers 
Oct4, Nanog, Sox-2 and SSEA-1 was performed; the clone showed positivity for 
all markers examined (Fig 29). 
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Fig 29 - Immunofluorescence assay of hybrid HM1 cl8. Oct4, Nanog, Sox-2 and SSEA-1 markers were 
tested; in each image are visible clones stained with an anti-Oct4, anti-Nanog, anti-Sox-2 and anti-SSEA-1 
antibody (fluorescent green signals), counterstained with DAPI (blue). All markers showed clear positivity.  
 
To complete the analysis of pluripotency in vitro, the presence of Nanog, OCT4 
and Sox2 pluripotency markers was also tested by reverse-transcription-PCR. As 
shown in Fig 30, all markers were expressed. GAPDH was used as cDNA 
positive control in that is a housekeeping gene; in the assay we used cDNA of 
HM1 cell line as positive control. HM1 cl8 expression was comparable to HM1 
parental line.  
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Fig 30 - RT-PCR analysis of pluripotency markers in the HM1 cl8 cells. We tested cDNA of HM1 cl8 cell 
line and cDNA of HM1 cell line, used as positive control. Housekeeping GAPDH, Nanog (top), OCT4 and 
SOX2 (bottom) cDNAs were analyzed. HM1 cl8 showed an expression comparable to the positive control 
for all markers analyzed. To the left of each marker the size (bp) of the amplified band is indicated. 
 
Finally, to test the capability of HM1 cl8 cells to differentiate in vivo, about two 
millions of cells were inoculated into the flanks of six-week-old CD-1-nu-nu 
mice, to test the ability to form teratoma structure. After three/four weeks mice 
were sacrificed, and the resected teratomas were fixed in 4% PFA and 
processed for paraffin sectioning and staining. According the analysis 
performed, the hybrid cl8 showed the capability to generate keratinized 
squamous epithelium (ectoderm), skeletal muscle (mesoderm) and ciliated 
epithelium goblets (endoderm). Therefore hybrid cl8 cells were able to generate 
all three germ layers as the original plurypotency stem cells (Fig 31).  
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Fig 31 - Histological analysis of teratoma formed three/four weeks after subcutaneous injection in 
immunocompromised six-week-old CD-1-nu-nu mice. The hybrid cl8 cells were able to generate all three 
germ layers as the HM1 parental pluripotent stem cells. The HM1 images represent nervous tissue 
(ectoderm), bone tissue (mesoderm) and ciliated epithelium (endoderm) from the left to the right. The 
HM1 cl8 images show keratinized squamous epithelium (ectoderm), skeletal muscle (mesoderm) and 
ciliated epithelium goblets (endoderm). Black arrows indicate the derived tissues (Hematoxylin and Eosin 
staining, 400x). Scale bar= 100 m. 
 
In conclusion, we were able to produce, by MMCT, ESC clones with an 
additional normal X chromosome, which corrects the genetic defect in the HPRT 
gene, as shown by the ability of the clones to grow in HAT medium. Some of 
these clones were karyotypically normal and maintain their pluripotency in spite 
of all the manipulation steps described above.  
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We have demonstrated that a single normal mouse X chromosome can be 
transferred from a donor cell line to a recipient cell line by using microcell-
mediated chromosome transfer (MMCT) protocol, with the final aim to cure 
inherited diseases caused by large gene deletions or rearrangements involving 
X chromosome. In fact, the classical gene therapy approaches do not allow the 
cure of diseases caused by large chromosomal rearrangements, due to the low 
efficiency of the available methods, or to the size limits of the vector used to 
convey therapeutic molecules. In our project we wanted to show that by using 
MMCT all the sequences and structures needed for proper expression of the 
affected gene(s) are transferred into the defective cell allowing the restoration 
of a complete large genomic region. 
 
To do that, we have therefore chosen as proof of principle of our project a X-
linked genetic disease, Lesch Nyhan syndrome (LN), which has been described 
to be due to both point mutations and large deletions involving the HPRT gene. 
In LN patients, the loss of the enzyme causes the impairment of the purine 
metabolism pathway, causing an over-production of uric acid. It is important to 
emphasize that so far LN disease does not has an effective cure yet, but only 
palliative treatments. Our goal was to demonstrate the efficiency of our gene 
therapy approach in this disease model, for which viable therapies do not yet 
exist. So, we chose the HM1 embryonic cell line that works as an excellent 
mouse model of the LN disease for in vitro manipulation; in fact the recipient 
HM1 stem cell line, a male line with normal chromosome content, carries a 
deletion in the HPRT gene. Furthermore, this cell line gave us the opportunity 
to use a very efficient selection system in vitro, the HAT selection medium.  
The HM1 cell line has been isolated directly from HPRT-deficient strain 129 
mice, and is characterized by a deletion of the HPRT gene, which extends from 
at least 10 kilobases 5' to the promoter up to the second intron of the genomic 
sequence (Doetschman et al., 1987; Thompson et al., 1989).  
5. Discussion  
 
85 
 
To perform our project, our first goal was to obtain a donor cell line, carrying at 
least one normal X chromosome, capable to efficiently form micronuclei. For the 
hybrid donor cell line generation we started from the A9 cell line. We have 
chosen this cell line because it was very efficient in micro-nucleation and has 
already been used by others to transfer single chromosomes (Kugoh et al., 
1999). The A9 cell line did not contain any normal X chromosome, as we have 
highlighted by FISH experiments using X mouse chromosome paint probe, 
confirming the data already present in literature. In addition, A9 is HPRT 
defective. 
 
So as a first step we performed a whole cells fusion experiment between the A9 
cell line and fetal fibroblasts (MEF) with PEG as fusogen agent. Our goal was to 
obtain a mono-chromosomic hybrid clone that presented an additional normal, 
MEF-derived X chromosome, together with the A9 chromosomes parental line. 
Since the acquired normal X chromosome provided the A9 cell line with a 
functional HPRT gene, the positive clones could be selected in HAT selective 
medium. 
Using this protocol, we obtained several clones. Our attention focused on two 
A9-like HAT resistant clones, C12 and B1, both having at least one whole X 
chromosome, as was demonstrated by the FISH experiments performed with 
the mouse X chromosome paint probe, and capable to form micronuclei in vitro 
after exposure to colchicine. The transferred chromosome was active, as was 
demonstrated through the survival C12 and B1 clones in HAT selective medium, 
because of the presence of an active HPRT gene. We also analyzed the 
chromosomal distribution for each clone obtained, and as we expected in each 
clone analyzed the median chromosome distribution was different, according to 
the random chromosome loss occurred after the fusion. 
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In the second step of the work, our goal was to transfer the normal X 
chromosome from the chromosomal donor HPRT+ line (A9/MEF clone) to the 
recipient HPRT- cell line (HM1). We selected the C12 hybrid clone as donor cell 
line due to its better ability to form micronuclei in vitro, despite having only one 
X chromosome and thus a lower probability to give rise the transfer than the B1 
clone.  
We set a microcell-mediated chromosome transfer (MMCT) protocol, adjusting 
the time of colchicine exposure and the time of cell fusion using the PEG 
fusogen. Indeed, after 48 h of C12 donor clone incubation with colchicine, we 
observed the highest number of micronuclei. Subsequently, after cytochalasin B 
digestion in a Percoll gradient centrifugation and subsequent filtration we 
obtained a crude microcell suspension completely free of A9 whole cells or large 
microcells consisting of more than one chromosome. Using small pore filters it 
was possible to collect the smaller microcells, then assumed carrying a single 
chromosome, compared to larger ones. Another critical point to be set was the 
PEG concentration and time of exposure. It is known that the optimal PEG 
concentration in culture ranges from 35% to 50%, because a lower 
concentration is better tolerate by cells but is also less efficient. So we set these 
parameters in an optimal way: 50% PEG for 1 min.  
All these conditions were used to perform the MMCT protocol.  
After obtaining the optimum microcells suspension, we fused these with an 
equal amount of monodispersed parental HM1 cells, and we re-plated the cells. 
The day after, the HAT selective medium was added. We obtained two HAT-
resistant clones, HM1 cl8 and cl1, both carrying a HM1-like structure, able to 
survive in HAT selective medium. By using C12 donor clone, our MMCT 
procedure was shown to have an efficiency of about 1/10-7. The efficiency of 
chromosome transfer was measured as the ratio between the number of HAT 
resistant clones and the number of microcells used.  
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The confirmation of the chromosome transfer in the recipient cell line, bearing 
the functional HPRT gene, was obtained by genomic HPRT PCR. Both MMCT 
clones obtained demonstrated the presence of both allelic forms of the gene, 
the mutated and the wild-type alleles. By chromosome distribution analysis we 
observed that our MMCT fusion protocol permitted the transfer of only one 
chromosome into the recipient line, as both clones showed a karyotype 2n =41 
chromosomes.  
 
Several reports of a single chromosome transfer have been present in 
literature, but many of them have not been characterized in detail by using 
cytogenetic and molecular technique. Therefore we performed a more detailed 
analysis on the HM1 clone 8 (cl8), which has showed greater chromosome 
stability in vitro. Analysis of the chromosome distribution, in fact, was 
performed both in cl8 and in the cl1 clones, and we found that in the first one 
the chromosome distribution was more stable, both by adding and removing 
the HAT selective medium (2n=41).  
 
To confirm the presence of two X chromosomes originating from two different 
parental lines we performed several genetic analyses.  
After showing by PCR the presence of both the mutated and the normal HPRT 
gene, we analyzed some SNP polymorphisms along the X chromosome to 
confirm the presence of a supernumerary chromosome derived from a different 
strain. We selected, in the C57 SNP database of NCBI, SNPs informative for our 
purpose and we investigated these in the clone. As expected, both the SNPs of 
cell donor line and the SNPs of the recipient cell line were present. This data, 
together with the presence of both allelic forms of the HPRT gene confirm the 
acquisition of an additional MEF-derived X chromosome. 
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Moreover, both the karyotype analysis and molecular cytogenetic approaches 
using FISH and M-FISH revealed the absence of rearrangements or aneuploidy 
in the MMCT cl8 genome. It is important to point out that through the classical 
DAPI banding the limit of resolution is about 2Mb, so the complete cytogenetic 
analysis was given by using the M-FISH technique, which ruled out 
translocations in the genome. Our approach, then, was shown to cure a genetic 
defect without causing macroscopic chromosome rearrangements in the 
recipient cell line. We can therefore conclude that our protocol allowed the 
maintenance of a normal karyotype, because we did not find, in the analyzed 
metaphases, rearrangements with the exception of the desired additional X 
chromosome. 
 
Finally, we wanted to show that our microcell fusion protocol does not alter the 
pluripotency of recipient cells used. Indeed, the analysis we conducted on the 
MMCT cl8 showed the ability to form teratomas in vivo, just like the HM1 
parental line. Following subcutaneous inoculum of MMCT cl8 cells in immuno-
compromised mice we obtained a well-differentiated teratoma. In fact, 
hematoxylin-eosin stained histological samples showed derivatives from all the 
three primordial germ layers, mesoderm, endoderm and ectoderm; this means 
that following MMCT, clones retained the ability to differentiate in vitro. 
Upon completion of this assay we also investigated the maintenance of 
pluripotency through the presence of alkaline phosphatase activity and the 
presence of classical stem cell markers, the latter both analyzed using cDNA 
PCR experiment and immunofluorescent assay. The presence of phosphatase 
alkaline activity is considered the first useful test to demonstrate the 
pluripotency of a cell line, and as expected the clone showed an activity 
comparable to the parental line. Similarly, the classic stemness markers 
investigated were found positive, by both RT-PCR and immunofluorescence 
analysis. Although the latter is a qualitative test, it can be stated that the 
presence of the Nanog, Oct4 and SOX-2 markers is apparently comparable to 
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that found in the parental HM1 cell line. All data collected allowed us to 
conclude that our protocol MMCT fusion did not affect the pluripotency of the 
cells used.  
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Several gene therapy approaches on genetic hereditary disease have been 
tested, including those based on homologous recombination and viral vectors. 
Because of the limits regarding these techniques, no strategy can be considered 
safe and efficient in all the clinical situations. 
Our gene therapy approach, by using MMCT, can be considered relatively 
innovative and safe. The transfer of an exogenous X chromosome into mutated 
cells has been not shown to cause chromosome rearrangements, involving 
autosomes or sex chromosomes. In the protocol we used, a whole X 
chromosome was transferred to a recipient HPRT-defective cell line, and this led 
to a supernumerary X chromosome-containing cell line. This does not represent 
a problem, in that aneuploidies involving the number of X chromosomes in 
literature are well described and are compatible with adult life, since the 
additional X chromosomes are inactivated in cells for dosage compensation.  
For our project we used the Lesch-Nyhan disease as a model of X-linked 
disease, but according to the data obtained, our MMCT protocol can be 
considered as an in vitro cell model to potentially cure all X-linked diseases. We 
can therefore say that, by using this protocol, we have demonstrated the 
capability to cure a genetic defect, leading to the complete rescue of the 
disease, without inducing chromosome rearrangements or insertional 
mutagenesis and conserving intact all the regulatory regions needed for a 
correct gene expression. 
Moreover, with regard to applications based on stem cells, it is noteworthy that 
the procedure did not alter the pluripotency of parental cells. This suggests that 
iPSC could be modified by MMCT and subsequently induced to differentiate 
toward the tissues needed for a specific disease. Our long-term goal is to allow 
the applicability of the method to cell therapy. 
We think that also in the field of synthetic biology, the possibility to transfer an 
intact single chromosome could be interesting. This could be relevant if the 
results by the Venter group will have to be extended to mammalian 
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chromosomes, although for this moment this appears to be a goal very far 
away.  
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